CleftGeneDB-Search

Gene: TGFB2

Basic information

Tag	Content
Uniprot ID	P61812; B4DKC5; P08112; Q15579; Q15581; Q4VAV9;
Entrez ID	7042
Genbank protein ID	EAW93326.1; AAR05442.1; AAH96235.1; AAA61162.1; AAH99635.1; CAA68279.1; AAA50405.1; AAA50404.1; BAG59137.1;
Genbank nucleotide ID	NM_001135599.3; NM_003238.4;
Ensembl protein ID	ENSP00000355897; ENSP00000355896;
Ensembl nucleotide ID	ENSG00000092969
Gene name	Transforming growth factor beta-2 proprotein
Gene symbol	TGFB2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	8454288; 10918043;
Functional description	Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.
Sequence	MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 EEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180 TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240 NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300 KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS 414

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1TFG
2TGI
4KXZ
5TX4
5TY4
6I9J

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	TGFB2	534069	P21214			Bos taurus	Prediction	More>>
1:1 ortholog	TGFB2	488596	F1PKH2			Canis lupus familiaris	Prediction	More>>
1:1 ortholog	TGFB2	100861228	A0A452FPN4			Capra hircus	Prediction	More>>
1:1 ortholog	TGFB2	100050377	F6WJJ3			Equus caballus	Prediction	More>>
1:1 ortholog	TGFB2	7042	P61812			Homo sapiens	Publication	More>>
1:1 ortholog	Tgfb2	21808	P27090	CPO	E12.5, E14.0, E13.5, E14.5, E15.5	Mus musculus	Publication	More>>
1:1 ortholog	TGFB2		A0A2I3S6G8			Pan troglodytes	Prediction	More>>
1:1 ortholog	TGFB2		F1S9L0			Sus scrofa	Prediction	More>>
1:1 ortholog	TGFB2		G1SNK8			Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Tgfb2		G3V6B1			Rattus norvegicus	Prediction	More>>
1:1 ortholog	tgfb2		F8W4A6			Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs187697359	p.His2Arg	missense variant	-	NC_000001.11:g.218346706A>G	1000Genomes,ExAC,gnomAD
rs776628524	p.Cys4Tyr	missense variant	-	NC_000001.11:g.218346712G>A	ExAC,gnomAD
rs1553292060	p.Leu6Pro	missense variant	-	NC_000001.11:g.218346718T>C	-
RCV000634159	p.Leu6Pro	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346718T>C	ClinVar
rs765477784	p.Ser7Asn	missense variant	-	NC_000001.11:g.218346721G>A	ExAC,gnomAD
rs763141894	p.Ala8Val	missense variant	-	NC_000001.11:g.218346724C>T	ExAC,TOPMed
rs752870701	p.Ala8Ser	missense variant	-	NC_000001.11:g.218346723G>T	ExAC,TOPMed
COSM4392068	p.Ile11Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218346733T>C	NCI-TCGA Cosmic
RCV000634163	p.His13Asn	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346738C>A	ClinVar
rs763918203	p.His13Asn	missense variant	-	NC_000001.11:g.218346738C>A	ExAC,TOPMed,gnomAD
RCV000347838	p.His13Asn	missense variant	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218346738C>A	ClinVar
rs1173342696	p.Thr16Met	missense variant	-	NC_000001.11:g.218346748C>T	TOPMed
rs1423446403	p.Thr16Ala	missense variant	-	NC_000001.11:g.218346747A>G	TOPMed
rs1334873734	p.Val17Ile	missense variant	-	NC_000001.11:g.218346750G>A	gnomAD
RCV000395786	p.Ala18Thr	missense variant	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218346753G>A	ClinVar
rs886045975	p.Ala18Thr	missense variant	-	NC_000001.11:g.218346753G>A	TOPMed
rs757201195	p.Ala18Val	missense variant	-	NC_000001.11:g.218346754C>T	ExAC,TOPMed,gnomAD
rs1305579825	p.Leu19Phe	missense variant	-	NC_000001.11:g.218346756C>T	gnomAD
rs1209272897	p.Leu27Phe	missense variant	-	NC_000001.11:g.218346780C>T	TOPMed
NCI-TCGA novel	p.Asp28Gly	missense variant	-	NC_000001.11:g.218346784A>G	NCI-TCGA
NCI-TCGA novel	p.Asp30Asn	missense variant	-	NC_000001.11:g.218346789G>A	NCI-TCGA
rs779872141	p.Phe32Leu	missense variant	-	NC_000001.11:g.218346795T>C	ExAC,gnomAD
rs748995213	p.Met33Ile	missense variant	-	NC_000001.11:g.218346800G>A	ExAC,gnomAD
RCV000769553	p.Met33Arg	missense variant	Thoracic aortic aneurysm and aortic dissection (TAAD)	NC_000001.11:g.218346799T>G	ClinVar
RCV000484113	p.Arg34His	missense variant	-	NC_000001.11:g.218346802G>A	ClinVar
rs1064796462	p.Arg34His	missense variant	-	NC_000001.11:g.218346802G>A	-
rs1318854254	p.Ser46Asn	missense variant	-	NC_000001.11:g.218346838G>A	TOPMed
RCV000786410	p.Leu48Arg	missense variant	-	NC_000001.11:g.218346844T>G	ClinVar
rs1553292088	p.Leu48Arg	missense variant	-	NC_000001.11:g.218346844T>G	-
RCV000620162	p.Leu48Arg	missense variant	-	NC_000001.11:g.218346844T>G	ClinVar
RCV000524041	p.Ser52Gly	missense variant	-	NC_000001.11:g.218346855A>G	ClinVar
rs1431335293	p.Ser52Arg	missense variant	-	NC_000001.11:g.218346857T>G	gnomAD
rs777159486	p.Ser52Thr	missense variant	-	NC_000001.11:g.218346856G>C	ExAC,gnomAD
rs771351240	p.Ser52Gly	missense variant	-	NC_000001.11:g.218346855A>G	ExAC,gnomAD
rs745960678	p.Pro53Leu	missense variant	-	NC_000001.11:g.218346859C>T	ExAC,gnomAD
RCV000493273	p.Pro54Ter	frameshift	-	NC_000001.11:g.218346857del	ClinVar
NCI-TCGA novel	p.Glu55ArgPheSerTerUnk	frameshift	-	NC_000001.11:g.218346857_218346858insC	NCI-TCGA
rs1359839189	p.Pro58Ser	missense variant	-	NC_000001.11:g.218346873C>T	gnomAD
rs763228811	p.Glu61Lys	missense variant	-	NC_000001.11:g.218346882G>A	ExAC,gnomAD
NCI-TCGA novel	p.Val63Gly	missense variant	-	NC_000001.11:g.218346889T>G	NCI-TCGA
rs1317014757	p.Pro64Leu	missense variant	-	NC_000001.11:g.218346892C>T	gnomAD
rs761602500	p.Pro64Ser	missense variant	-	NC_000001.11:g.218346891C>T	ExAC,gnomAD
RCV000546758	p.Pro65Ser	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346894C>T	ClinVar
RCV000200048	p.Pro65Leu	missense variant	-	NC_000001.11:g.218346895C>T	ClinVar
rs747128130	p.Pro65Ser	missense variant	-	NC_000001.11:g.218346894C>T	ExAC,TOPMed,gnomAD
rs750324465	p.Pro65Leu	missense variant	-	NC_000001.11:g.218346895C>T	ExAC,TOPMed,gnomAD
rs747128130	p.Pro65Ala	missense variant	-	NC_000001.11:g.218346894C>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Pro65Gln	missense variant	-	NC_000001.11:g.218346895C>A	NCI-TCGA
RCV000765072	p.Pro65Leu	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218346895C>T	ClinVar
rs1202024276	p.Glu66Ala	missense variant	-	NC_000001.11:g.218346898A>C	gnomAD
RCV000765073	p.Val67Met	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218346900G>A	ClinVar
rs201761868	p.Val67Met	missense variant	-	NC_000001.11:g.218346900G>A	ESP,ExAC,TOPMed,gnomAD
RCV000249446	p.Val67Met	missense variant	-	NC_000001.11:g.218346900G>A	ClinVar
RCV000696533	p.Val67Met	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346900G>A	ClinVar
RCV000200774	p.Val67Met	missense variant	-	NC_000001.11:g.218346900G>A	ClinVar
RCV000477625	p.Ile70Thr	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346910T>C	ClinVar
rs1027195424	p.Ile70Thr	missense variant	-	NC_000001.11:g.218346910T>C	TOPMed,gnomAD
RCV000428017	p.Tyr71Ter	nonsense	-	NC_000001.11:g.218346914C>A	ClinVar
rs766024374	p.Tyr71Ter	stop gained	-	NC_000001.11:g.218346914C>A	ExAC
rs753391734	p.Ser73Gly	missense variant	-	NC_000001.11:g.218346918A>G	ExAC,gnomAD
rs1400029652	p.Thr74Ser	missense variant	-	NC_000001.11:g.218346921A>T	TOPMed
NCI-TCGA novel	p.Arg75Met	missense variant	-	NC_000001.11:g.218346925G>T	NCI-TCGA
RCV000623776	p.Leu77Ter	frameshift	Inborn genetic diseases	NC_000001.11:g.218346930_218346946del	ClinVar
rs371241859	p.Gln79Arg	missense variant	-	NC_000001.11:g.218346937A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000621812	p.Gln79Arg	missense variant	-	NC_000001.11:g.218346937A>G	ClinVar
RCV000196118	p.Gln79Arg	missense variant	-	NC_000001.11:g.218346937A>G	ClinVar
RCV000557999	p.Gln79Arg	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346937A>G	ClinVar
NCI-TCGA novel	p.Glu80Ter	stop gained	-	NC_000001.11:g.218346939G>T	NCI-TCGA
rs1358538309	p.Lys81Arg	missense variant	-	NC_000001.11:g.218346943A>G	gnomAD
rs1426532619	p.Ala82Ser	missense variant	-	NC_000001.11:g.218346945G>T	gnomAD
rs757596095	p.Ser83Arg	missense variant	-	NC_000001.11:g.218346950C>A	ExAC,gnomAD
rs757596095	p.Ser83Arg	missense variant	-	NC_000001.11:g.218346950C>G	ExAC,gnomAD
rs781392453	p.Arg84Leu	missense variant	-	NC_000001.11:g.218346952G>T	ExAC,gnomAD
rs781392453	p.Arg84Gln	missense variant	-	NC_000001.11:g.218346952G>A	ExAC,gnomAD
RCV000472775	p.Arg85Ter	frameshift	Holt-Oram syndrome (HOS)	NC_000001.11:g.218346953dup	ClinVar
NCI-TCGA novel	p.Ala86Val	missense variant	-	NC_000001.11:g.218346958C>T	NCI-TCGA
rs775606572	p.Cys89Phe	missense variant	-	NC_000001.11:g.218346967G>T	ExAC,gnomAD
rs770283888	p.Cys89Arg	missense variant	-	NC_000001.11:g.218346966T>C	ExAC,gnomAD
rs749309877	p.Glu90Lys	missense variant	-	NC_000001.11:g.218346969G>A	ExAC,gnomAD
RCV000508622	p.Arg91His	missense variant	Hirschsprung disease 1 (HSCR1)	NC_000001.11:g.218346973G>A	ClinVar
rs10482721	p.Arg91His	missense variant	-	NC_000001.11:g.218346973G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs774592518	p.Glu92Ala	missense variant	-	NC_000001.11:g.218346976A>C	ExAC,gnomAD
rs761533776	p.Arg93Thr	missense variant	-	NC_000001.11:g.218346979G>C	ExAC,gnomAD
RCV000622134	p.Ser94Ter	frameshift	-	NC_000001.11:g.218346981del	ClinVar
rs767393318	p.Asp95Glu	missense variant	-	NC_000001.11:g.218346986C>G	ExAC,TOPMed,gnomAD
rs767393318	p.Asp95Glu	missense variant	-	NC_000001.11:g.218346986C>A	ExAC,TOPMed,gnomAD
RCV000210467	p.Tyr99Ter	nonsense	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218346998C>A	ClinVar
rs760759052	p.Tyr99Ter	stop gained	-	NC_000001.11:g.218346998C>A	ExAC,TOPMed,gnomAD
rs959815933	p.Ala100Pro	missense variant	-	NC_000001.11:g.218346999G>C	TOPMed
rs992485773	p.Ala100Gly	missense variant	-	NC_000001.11:g.218347000C>G	TOPMed
VAR_068931	p.Ala100_Tyr104del	inframe_deletion	Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]	-	UniProt
rs766401610	p.Lys101Gln	missense variant	-	NC_000001.11:g.218347002A>C	ExAC,gnomAD
rs967581444	p.Glu102Gly	missense variant	-	NC_000001.11:g.218347006A>G	TOPMed,gnomAD
VAR_080342	p.Glu102_Ser414del	inframe_deletion	Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]	-	UniProt
rs1403363066	p.Tyr104Cys	missense variant	-	NC_000001.11:g.218347012A>G	gnomAD
RCV000462439	p.Met108Leu	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218347023A>T	ClinVar
rs1060501982	p.Met108Leu	missense variant	-	NC_000001.11:g.218347023A>T	-
rs1354740126	p.Pro110His	missense variant	-	NC_000001.11:g.218347030C>A	gnomAD
rs757959311	p.Phe111Val	missense variant	-	NC_000001.11:g.218347032T>G	ExAC,gnomAD
NCI-TCGA novel	p.Phe111SerPheSerTerUnkUnk	frameshift	-	NC_000001.11:g.218347028G>-	NCI-TCGA
rs370808888	p.Phe112Leu	missense variant	-	NC_000001.11:g.218347037C>G	ESP,ExAC,TOPMed,gnomAD
rs1553292141	p.Phe112Leu	missense variant	-	NC_000001.11:g.218347035T>C	-
RCV000546519	p.Phe112Leu	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218347035T>C	ClinVar
RCV000444603	p.Pro113Leu	missense variant	-	NC_000001.11:g.218347039C>T	ClinVar
rs1057524627	p.Pro113Leu	missense variant	-	NC_000001.11:g.218347039C>T	TOPMed,gnomAD
rs1316319151	p.Ser114Pro	missense variant	-	NC_000001.11:g.218347041T>C	gnomAD
rs146933799	p.Ala117Val	missense variant	-	NC_000001.11:g.218405172C>T	1000Genomes
rs149533093	p.Pro119Leu	missense variant	-	NC_000001.11:g.218405178C>T	ESP,ExAC,TOPMed,gnomAD
RCV000198360	p.Pro119Ter	frameshift	-	NC_000001.11:g.218405178del	ClinVar
RCV000769556	p.Pro119Leu	missense variant	Thoracic aortic aneurysm and aortic dissection (TAAD)	NC_000001.11:g.218405178C>T	ClinVar
RCV000415640	p.Pro119Leu	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218405178C>T	ClinVar
RCV000621239	p.Pro119Leu	missense variant	-	NC_000001.11:g.218405178C>T	ClinVar
NCI-TCGA novel	p.Pro119Ser	missense variant	-	NC_000001.11:g.218405177C>T	NCI-TCGA
RCV000583868	p.Pro119Leu	missense variant	Aortic aneurysm	NC_000001.11:g.218405178C>T	ClinVar
rs1300823855	p.Thr121Ser	missense variant	-	NC_000001.11:g.218405184C>G	TOPMed,gnomAD
RCV000520853	p.Thr121Ser	missense variant	-	NC_000001.11:g.218405184C>G	ClinVar
NCI-TCGA novel	p.Thr121Ile	missense variant	-	NC_000001.11:g.218405184C>T	NCI-TCGA
RCV000707281	p.Thr121Ser	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218405184C>G	ClinVar
rs755563719	p.Tyr123Cys	missense variant	-	NC_000001.11:g.218405190A>G	ExAC,gnomAD
RCV000208163	p.Arg124Ter	frameshift	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218405192dup	ClinVar
RCV000200239	p.Arg124Lys	missense variant	-	NC_000001.11:g.218405193G>A	ClinVar
rs863223789	p.Arg124Lys	missense variant	-	NC_000001.11:g.218405193G>A	TOPMed
rs779228043	p.Pro125Arg	missense variant	-	NC_000001.11:g.218405196C>G	ExAC,gnomAD
rs752823052	p.Ile129Thr	missense variant	-	NC_000001.11:g.218405208T>C	ExAC,TOPMed,gnomAD
RCV000634164	p.Arg131Ter	nonsense	Holt-Oram syndrome (HOS)	NC_000001.11:g.218405213C>T	ClinVar
rs869025531	p.Arg131Ter	stop gained	-	NC_000001.11:g.218405213C>T	-
rs758366080	p.Arg131Gln	missense variant	-	NC_000001.11:g.218405214G>A	ExAC,TOPMed,gnomAD
rs777980933	p.Phe132Ile	missense variant	-	NC_000001.11:g.218405216T>A	ExAC,gnomAD
rs757551766	p.Val134Ile	missense variant	-	NC_000001.11:g.218405222G>A	ExAC,TOPMed,gnomAD
rs1209069485	p.Ala136Thr	missense variant	-	NC_000001.11:g.218405228G>A	gnomAD
rs1264824521	p.Met137Thr	missense variant	-	NC_000001.11:g.218405232T>C	gnomAD
rs967408802	p.Met137Ile	missense variant	-	NC_000001.11:g.218405233G>A	TOPMed
RCV000618744	p.Met137Thr	missense variant	-	NC_000001.11:g.218405232T>C	ClinVar
RCV000414052	p.Asn140Ter	frameshift	-	NC_000001.11:g.218405241del	ClinVar
rs141548795	p.Asn143Ser	missense variant	-	NC_000001.11:g.218405250A>G	ESP,ExAC,TOPMed,gnomAD
rs1362716412	p.Leu144Phe	missense variant	-	NC_000001.11:g.218405254G>C	gnomAD
rs1439580016	p.Val145Met	missense variant	-	NC_000001.11:g.218405255G>A	gnomAD
NCI-TCGA novel	p.Glu148Gln	missense variant	-	NC_000001.11:g.218405264G>C	NCI-TCGA
RCV000534948	p.Phe149Val	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218405267T>G	ClinVar
rs896156575	p.Phe149Val	missense variant	-	NC_000001.11:g.218405267T>G	-
NCI-TCGA novel	p.Arg150Ile	missense variant	-	NC_000001.11:g.218405271G>T	NCI-TCGA
COSM1229084	p.Arg153Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218405279C>T	NCI-TCGA Cosmic
RCV000414990	p.Arg153His	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218405280G>A	ClinVar
rs1057518684	p.Arg153His	missense variant	-	NC_000001.11:g.218405280G>A	TOPMed
rs1425658948	p.Gln155Lys	missense variant	-	NC_000001.11:g.218405285C>A	TOPMed,gnomAD
rs1293375727	p.Gln155Pro	missense variant	-	NC_000001.11:g.218405286A>C	gnomAD
RCV000617492	p.Lys158Asn	missense variant	-	NC_000001.11:g.218405296A>T	ClinVar
rs1445749036	p.Lys158Glu	missense variant	-	NC_000001.11:g.218405294A>G	gnomAD
rs775251473	p.Lys158Asn	missense variant	-	NC_000001.11:g.218405296A>T	ExAC,gnomAD
rs748852886	p.Arg160Thr	missense variant	-	NC_000001.11:g.218405301G>C	ExAC,gnomAD
rs1160416926	p.Val161Gly	missense variant	-	NC_000001.11:g.218405304T>G	TOPMed
rs768202434	p.Pro162Leu	missense variant	-	NC_000001.11:g.218405307C>T	ExAC,gnomAD
RCV000619100	p.Arg165Trp	missense variant	-	NC_000001.11:g.218405315C>T	ClinVar
RCV000467653	p.Arg165Trp	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218405315C>T	ClinVar
rs773820426	p.Arg165Trp	missense variant	-	NC_000001.11:g.218405315C>T	ExAC,TOPMed,gnomAD
rs1291056000	p.Leu172Phe	missense variant	-	NC_000001.11:g.218434085C>T	gnomAD
NCI-TCGA novel	p.Leu172Ile	missense variant	-	NC_000001.11:g.218434085C>A	NCI-TCGA
COSM4028310	p.Lys173Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434089A>C	NCI-TCGA Cosmic
rs749692412	p.Lys173Arg	missense variant	-	NC_000001.11:g.218434089A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Asp176Tyr	missense variant	-	NC_000001.11:g.218434097G>T	NCI-TCGA
COSM3803920	p.Leu177Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434100T>G	NCI-TCGA Cosmic
COSM265868	p.Leu177Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000001.11:g.218434101T>G	NCI-TCGA Cosmic
rs774826853	p.Thr178Ile	missense variant	-	NC_000001.11:g.218434104C>T	ExAC,gnomAD
rs929597621	p.Ser179Cys	missense variant	-	NC_000001.11:g.218434107C>G	TOPMed,gnomAD
NCI-TCGA novel	p.Ser179Phe	missense variant	-	NC_000001.11:g.218434107C>T	NCI-TCGA
COSM1290118	p.Thr181Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434112A>G	NCI-TCGA Cosmic
rs772616801	p.Thr181Ile	missense variant	-	NC_000001.11:g.218434113C>T	ExAC,gnomAD
RCV000157514	p.Gln182Ter	nonsense	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218434115C>T	ClinVar
rs730880221	p.Gln182Ter	stop gained	-	NC_000001.11:g.218434115C>T	-
RCV000619024	p.Arg183His	missense variant	-	NC_000001.11:g.218434119G>A	ClinVar
rs1436552875	p.Arg183Cys	missense variant	-	NC_000001.11:g.218434118C>T	TOPMed,gnomAD
rs773177511	p.Arg183His	missense variant	-	NC_000001.11:g.218434119G>A	ExAC,gnomAD
RCV000660311	p.Arg183Cys	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218434118C>T	ClinVar
RCV000817127	p.Arg183His	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218434119G>A	ClinVar
RCV000696874	p.Ile185Val	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218434124A>G	ClinVar
rs754008150	p.Asp186Gly	missense variant	-	NC_000001.11:g.218434128A>G	ExAC,gnomAD
rs766536496	p.Asp186Asn	missense variant	-	NC_000001.11:g.218434127G>A	ExAC,TOPMed,gnomAD
rs759729701	p.Ser187Gly	missense variant	-	NC_000001.11:g.218434130A>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val189GlyPheSerTerUnkUnk	frameshift	-	NC_000001.11:g.218434137_218434140TTGT>-	NCI-TCGA
RCV000482233	p.Arg193Ter	frameshift	-	NC_000001.11:g.218434147_218434148del	ClinVar
RCV000617310	p.Arg193Ter	frameshift	-	NC_000001.11:g.218434147_218434148del	ClinVar
rs765086663	p.Arg193Thr	missense variant	-	NC_000001.11:g.218434149G>C	ExAC,gnomAD
rs1375258583	p.Ala194Ser	missense variant	-	NC_000001.11:g.218434151G>T	gnomAD
NCI-TCGA novel	p.Ala194Glu	missense variant	-	NC_000001.11:g.218434152C>A	NCI-TCGA
COSM4930325	p.Glu195Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434155A>T	NCI-TCGA Cosmic
rs863223790	p.Glu195Ter	stop gained	-	NC_000001.11:g.218434154G>T	-
RCV000634160	p.Glu195Ter	nonsense	Holt-Oram syndrome (HOS)	NC_000001.11:g.218434154G>T	ClinVar
RCV000199064	p.Glu195Ter	nonsense	-	NC_000001.11:g.218434154G>T	ClinVar
RCV000275080	p.Glu197Lys	missense variant	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218434160G>A	ClinVar
rs764028978	p.Glu197Lys	missense variant	-	NC_000001.11:g.218434160G>A	ExAC,gnomAD
NCI-TCGA novel	p.Glu197AspIlePheTer	stop gained	-	NC_000001.11:g.218434160_218434161insACATATTTT	NCI-TCGA
RCV000536008	p.Glu197Lys	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218434160G>A	ClinVar
NCI-TCGA novel	p.Trp198Ter	stop gained	-	NC_000001.11:g.218434165G>A	NCI-TCGA
rs1015033324	p.Ser200Phe	missense variant	-	NC_000001.11:g.218434170C>T	TOPMed
rs1275341384	p.Asp202Asn	missense variant	-	NC_000001.11:g.218434175G>A	gnomAD
COSM6061074	p.Asp205Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434185A>T	NCI-TCGA Cosmic
rs796790344	p.Asp205His	missense variant	-	NC_000001.11:g.218434184G>C	gnomAD
COSM904013	p.Ala206Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434188C>A	NCI-TCGA Cosmic
RCV000415676	p.Val207Leu	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218434190G>C	ClinVar
rs10482810	p.Val207Leu	missense variant	-	NC_000001.11:g.218434190G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs745557994	p.Val207Ala	missense variant	-	NC_000001.11:g.218434191T>C	ExAC,gnomAD
COSM4028314	p.His208Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434194A>G	NCI-TCGA Cosmic
rs755821914	p.His208Gln	missense variant	-	NC_000001.11:g.218434195T>G	ExAC,TOPMed,gnomAD
rs916820522	p.His208Tyr	missense variant	-	NC_000001.11:g.218434193C>T	TOPMed
NCI-TCGA novel	p.Trp210Cys	missense variant	-	NC_000001.11:g.218434201G>C	NCI-TCGA
rs779476673	p.Leu211Ile	missense variant	-	NC_000001.11:g.218434202C>A	ExAC,TOPMed,gnomAD
rs773724269	p.His213Gln	missense variant	-	NC_000001.11:g.218434210T>A	ExAC,gnomAD
rs773724269	p.His213Gln	missense variant	-	NC_000001.11:g.218434210T>G	ExAC,gnomAD
rs772460840	p.His213Arg	missense variant	-	NC_000001.11:g.218434209A>G	ExAC,gnomAD
NCI-TCGA novel	p.His213Asn	missense variant	-	NC_000001.11:g.218434208C>A	NCI-TCGA
rs1342706944	p.Asp215Glu	missense variant	-	NC_000001.11:g.218434339C>G	TOPMed,gnomAD
RCV000195595	p.Arg216Ter	frameshift	-	NC_000001.11:g.218434338_218434339insT	ClinVar
NCI-TCGA novel	p.Gly219Glu	missense variant	-	NC_000001.11:g.218434350G>A	NCI-TCGA
RCV000195866	p.Lys221Asn	missense variant	-	NC_000001.11:g.218434357A>T	ClinVar
rs863223791	p.Lys221Asn	missense variant	-	NC_000001.11:g.218434357A>T	-
rs957164399	p.Ser223Asn	missense variant	-	NC_000001.11:g.218434362G>A	TOPMed,gnomAD
rs957164399	p.Ser223Ile	missense variant	-	NC_000001.11:g.218434362G>T	TOPMed,gnomAD
RCV000389271	p.Leu224Val	missense variant	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218434364T>G	ClinVar
rs886045978	p.Leu224Val	missense variant	-	NC_000001.11:g.218434364T>G	TOPMed
rs766148763	p.Pro227Ala	missense variant	-	NC_000001.11:g.218434373C>G	ExAC,gnomAD
NCI-TCGA novel	p.Cys228Ter	stop gained	-	NC_000001.11:g.218434378C>A	NCI-TCGA
rs1185241582	p.Cys229Phe	missense variant	-	NC_000001.11:g.218434380G>T	TOPMed
rs398122885	p.Cys229Ter	stop gained	Loeys-dietz syndrome 4 (lds4)	NC_000001.11:g.218434381C>A	gnomAD
RCV000030735	p.Cys229Ter	nonsense	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218434381C>A	ClinVar
VAR_080343	p.Cys229_Ser414del	inframe_deletion	Loeys-Dietz syndrome 4 (LDS4) [MIM:614816]	-	UniProt
rs1197477871	p.Thr230Ala	missense variant	-	NC_000001.11:g.218434382A>G	gnomAD
rs753572174	p.Pro233Ser	missense variant	-	NC_000001.11:g.218434391C>T	ExAC,gnomAD
rs1477299082	p.Pro233Leu	missense variant	-	NC_000001.11:g.218434392C>T	gnomAD
NCI-TCGA novel	p.Asn235Thr	missense variant	-	NC_000001.11:g.218434398A>C	NCI-TCGA
RCV000494411	p.Ile239Phe	missense variant	-	NC_000001.11:g.218434409A>T	ClinVar
rs1131691445	p.Ile239Phe	missense variant	-	NC_000001.11:g.218434409A>T	-
COSM4028316	p.Lys242Asn	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218434420A>C	NCI-TCGA Cosmic
RCV000695724	p.Glu247Lys	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218434433G>A	ClinVar
RCV000826057	p.Glu247Lys	missense variant	-	NC_000001.11:g.218434433G>A	ClinVar
rs751816387	p.Ala248Val	missense variant	-	NC_000001.11:g.218434437C>T	ExAC,gnomAD
rs778265133	p.Ala248Thr	missense variant	-	NC_000001.11:g.218434436G>A	ExAC,gnomAD
rs781637645	p.Arg249Ile	missense variant	-	NC_000001.11:g.218434440G>T	ExAC,gnomAD
rs769911912	p.Ala251Ser	missense variant	-	NC_000001.11:g.218434445G>T	ExAC,gnomAD
rs1309844427	p.Ala251Gly	missense variant	-	NC_000001.11:g.218434446C>G	gnomAD
rs1322126863	p.Ile253Thr	missense variant	-	NC_000001.11:g.218435973T>C	gnomAD
rs1553303162	p.IleAsp253IleTyr	missense variant	-	NC_000001.11:g.218435974_218435975delinsAT	-
RCV000634161	p.Asp254Tyr	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218435974_218435975delinsAT	ClinVar
RCV000619487	p.Gly255Asp	missense variant	-	NC_000001.11:g.218435979G>A	ClinVar
rs781514831	p.Gly255Asp	missense variant	-	NC_000001.11:g.218435979G>A	ExAC,gnomAD
rs1263309543	p.Ser257Phe	missense variant	-	NC_000001.11:g.218435985C>T	gnomAD
RCV000688014	p.Thr258Ile	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218435988C>T	ClinVar
rs373352179	p.Thr258Ile	missense variant	-	NC_000001.11:g.218435988C>T	ESP,ExAC,TOPMed,gnomAD
RCV000419049	p.Thr258Ile	missense variant	-	NC_000001.11:g.218435988C>T	ClinVar
RCV000769560	p.Tyr259Asp	missense variant	Thoracic aortic aneurysm and aortic dissection (TAAD)	NC_000001.11:g.218435990T>G	ClinVar
rs1212341043	p.Tyr259Asp	missense variant	-	NC_000001.11:g.218435990T>G	TOPMed
rs191509998	p.Ser261Asn	missense variant	-	NC_000001.11:g.218435997G>A	1000Genomes,ExAC,gnomAD
rs1256878861	p.Asp263Glu	missense variant	-	NC_000001.11:g.218436004T>G	gnomAD
RCV000246433	p.Lys265Glu	missense variant	-	NC_000001.11:g.218436008A>G	ClinVar
rs886038965	p.Lys265Glu	missense variant	-	NC_000001.11:g.218436008A>G	-
rs1356922676	p.Thr266Asn	missense variant	-	NC_000001.11:g.218436012C>A	TOPMed
NCI-TCGA novel	p.Thr266Ala	missense variant	-	NC_000001.11:g.218436011A>G	NCI-TCGA
rs1300063075	p.Ile267Val	missense variant	-	NC_000001.11:g.218436014A>G	gnomAD
NCI-TCGA novel	p.Lys268Asn	missense variant	-	NC_000001.11:g.218436019G>C	NCI-TCGA
COSM3360673	p.Ser269Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218436021C>T	NCI-TCGA Cosmic
rs749266746	p.Thr270Pro	missense variant	-	NC_000001.11:g.218436023A>C	ExAC,gnomAD
rs947761185	p.Thr270Ser	missense variant	-	NC_000001.11:g.218436024C>G	TOPMed,gnomAD
rs749266746	p.Thr270Ala	missense variant	-	NC_000001.11:g.218436023A>G	ExAC,gnomAD
rs370439281	p.Arg271Lys	missense variant	-	NC_000001.11:g.218436027G>A	ESP,TOPMed,gnomAD
rs1415933135	p.Lys272Asn	missense variant	-	NC_000001.11:g.218436031A>C	gnomAD
rs1187360350	p.Lys272Glu	missense variant	-	NC_000001.11:g.218436029A>G	gnomAD
rs747979194	p.Lys273Arg	missense variant	-	NC_000001.11:g.218436033A>G	ExAC,gnomAD
rs1467391590	p.Lys273Glu	missense variant	-	NC_000001.11:g.218436032A>G	TOPMed,gnomAD
COSM4613307	p.Asn274LysPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000001.11:g.218436028_218436029insA	NCI-TCGA Cosmic
COSM1180713	p.Asn274ThrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000001.11:g.218436029A>-	NCI-TCGA Cosmic
RCV000197799	p.Asn274Ter	frameshift	-	NC_000001.11:g.218436036dup	ClinVar
rs559315266	p.Asn274Ser	missense variant	-	NC_000001.11:g.218436036A>G	1000Genomes,ExAC,gnomAD
rs559315266	p.Asn274Thr	missense variant	-	NC_000001.11:g.218436036A>C	1000Genomes,ExAC,gnomAD
RCV000507174	p.Asn274Ter	frameshift	-	NC_000001.11:g.218436036dup	ClinVar
RCV000542520	p.Ser275Gly	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436038A>G	ClinVar
rs139825195	p.Ser275Gly	missense variant	-	NC_000001.11:g.218436038A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1169804851	p.Gly276Arg	missense variant	-	NC_000001.11:g.218436041G>A	TOPMed
rs1304484008	p.Lys277Asn	missense variant	-	NC_000001.11:g.218436046G>T	gnomAD
rs1395226344	p.Thr278Ile	missense variant	-	NC_000001.11:g.218436048C>T	TOPMed,gnomAD
rs760758897	p.Thr278Ala	missense variant	-	NC_000001.11:g.218436047A>G	ExAC,gnomAD
rs1310329224	p.Leu281Phe	missense variant	-	NC_000001.11:g.218436056C>T	gnomAD
RCV000686958	p.Leu282Pro	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436060T>C	ClinVar
rs1276969502	p.Tyr289Cys	missense variant	-	NC_000001.11:g.218436081A>G	gnomAD
rs1373735073	p.Arg290Ile	missense variant	-	NC_000001.11:g.218436084G>T	gnomAD
NCI-TCGA novel	p.Leu291Pro	missense variant	-	NC_000001.11:g.218436087T>C	NCI-TCGA
rs1420202420	p.Glu292Lys	missense variant	-	NC_000001.11:g.218436089G>A	TOPMed
rs758931687	p.Ser293Leu	missense variant	-	NC_000001.11:g.218436093C>T	ExAC,gnomAD
rs1165937586	p.Gln294Arg	missense variant	-	NC_000001.11:g.218436096A>G	TOPMed
RCV000550583	p.Arg298Ter	frameshift	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436107_218436116del	ClinVar
rs1200175663	p.Arg298Trp	missense variant	-	NC_000001.11:g.218436107C>T	TOPMed,gnomAD
rs762561484	p.Arg298Gln	missense variant	-	NC_000001.11:g.218436108G>A	ExAC,TOPMed,gnomAD
RCV000806655	p.Arg298Gln	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436108G>A	ClinVar
RCV000198949	p.Arg298Gln	missense variant	-	NC_000001.11:g.218436108G>A	ClinVar
COSM6061072	p.Arg299Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218436111G>T	NCI-TCGA Cosmic
rs1057521150	p.Arg299Gln	missense variant	-	NC_000001.11:g.218436111G>A	-
RCV000660312	p.Arg299Gln	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218436111G>A	ClinVar
RCV000811636	p.Arg299Trp	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436110C>T	ClinVar
rs863223792	p.Arg299Trp	missense variant	-	NC_000001.11:g.218436110C>T	-
RCV000210465	p.Arg299Trp	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218436110C>T	ClinVar
NCI-TCGA novel	p.Lys300Thr	missense variant	-	NC_000001.11:g.218436114A>C	NCI-TCGA
rs869312903	p.Arg302Cys	missense variant	-	NC_000001.11:g.218436119C>T	-
rs869312903	p.Arg302Ser	missense variant	-	NC_000001.11:g.218436119C>A	-
RCV000509486	p.Arg302His	missense variant	-	NC_000001.11:g.218436120G>A	ClinVar
rs1553303213	p.Arg302His	missense variant	-	NC_000001.11:g.218436120G>A	-
RCV000688826	p.Arg302Cys	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436119C>T	ClinVar
RCV000229032	p.Arg302Ser	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436119C>A	ClinVar
RCV000255040	p.Arg302Cys	missense variant	-	NC_000001.11:g.218436119C>T	ClinVar
rs1478901182	p.Leu304Val	missense variant	-	NC_000001.11:g.218436125T>G	gnomAD
RCV000526438	p.Asp305Glu	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218436130T>A	ClinVar
rs1194682711	p.AspAlaAlaTyrCysPheArg305AspAlaAlaTyrCysPheArgCysGlyLeuLeuLeuTerUnk	stop gained	-	NC_000001.11:g.218436147_218436148insATGCGGCCTATTGCTTTAG	gnomAD
rs1553303217	p.Asp305Glu	missense variant	-	NC_000001.11:g.218436130T>A	-
rs989462091	p.Ala306Val	missense variant	-	NC_000001.11:g.218436132C>T	TOPMed,gnomAD
rs989462091	p.Ala306Glu	missense variant	-	NC_000001.11:g.218436132C>A	TOPMed,gnomAD
rs1178400838	p.Ala307Thr	missense variant	-	NC_000001.11:g.218436134G>A	gnomAD
rs750774144	p.Tyr308Ser	missense variant	-	NC_000001.11:g.218436138A>C	ExAC,gnomAD
RCV000479243	p.Arg311Lys	missense variant	-	NC_000001.11:g.218436147G>A	ClinVar
rs1064793278	p.Arg311Lys	missense variant	-	NC_000001.11:g.218436147G>A	-
rs1241255536	p.Arg311Ser	missense variant	-	NC_000001.11:g.218437343A>C	gnomAD
rs200149375	p.Val313Leu	missense variant	-	NC_000001.11:g.218437347G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs200149375	p.Val313Met	missense variant	-	NC_000001.11:g.218437347G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs754350645	p.Asn316Ser	missense variant	-	NC_000001.11:g.218437357A>G	ExAC,gnomAD
rs1553303351	p.Cys317Ser	missense variant	-	NC_000001.11:g.218437360G>C	-
RCV000539015	p.Cys317Ser	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218437360G>C	ClinVar
COSM6124212	p.Cys318Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218437363G>A	NCI-TCGA Cosmic
RCV000197949	p.Cys318Phe	missense variant	-	NC_000001.11:g.218437363G>T	ClinVar
rs863223793	p.Cys318Phe	missense variant	-	NC_000001.11:g.218437363G>T	-
RCV000585795	p.Arg320Cys	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218437368C>T	ClinVar
rs896426406	p.Arg320His	missense variant	-	NC_000001.11:g.218437369G>A	TOPMed,gnomAD
rs1553303352	p.Arg320Cys	missense variant	-	NC_000001.11:g.218437368C>T	UniProt,dbSNP
VAR_072740	p.Arg320Cys	missense variant	-	NC_000001.11:g.218437368C>T	UniProt
rs1553303352	p.Arg320Cys	missense variant	Loeys-dietz syndrome 4 (lds4)	NC_000001.11:g.218437368C>T	-
rs765295855	p.Pro321Thr	missense variant	-	NC_000001.11:g.218437371C>A	ExAC,TOPMed,gnomAD
COSM6061070	p.Tyr323Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218437378A>G	NCI-TCGA Cosmic
rs752807885	p.Tyr323His	missense variant	-	NC_000001.11:g.218437377T>C	ExAC,TOPMed,gnomAD
RCV000756773	p.Ile324Val	missense variant	-	NC_000001.11:g.218437380A>G	ClinVar
rs866788278	p.Ile324Val	missense variant	-	NC_000001.11:g.218437380A>G	-
RCV000489022	p.Lys327Asn	missense variant	-	NC_000001.11:g.218437391G>T	ClinVar
rs1085307561	p.Lys327Asn	missense variant	-	NC_000001.11:g.218437391G>T	-
rs758704356	p.Arg328Lys	missense variant	-	NC_000001.11:g.218437393G>A	ExAC,gnomAD
rs1348984007	p.Asp329His	missense variant	-	NC_000001.11:g.218437395G>C	gnomAD
rs746826425	p.Gly331Arg	missense variant	-	NC_000001.11:g.218437401G>A	ExAC,gnomAD
rs1190246942	p.Lys333Asn	missense variant	-	NC_000001.11:g.218437409A>T	TOPMed
NCI-TCGA novel	p.Trp334Cys	missense variant	-	NC_000001.11:g.218437412G>T	NCI-TCGA
NCI-TCGA novel	p.His336Gln	missense variant	-	NC_000001.11:g.218437418C>G	NCI-TCGA
rs575279686	p.Glu337Gly	missense variant	-	NC_000001.11:g.218437420A>G	1000Genomes,ExAC,gnomAD
rs387907278	p.Pro338His	missense variant	Loeys-dietz syndrome 4 (lds4)	NC_000001.11:g.218437423C>A	-
rs387907278	p.Pro338His	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218437423C>A	UniProt,dbSNP
VAR_068934	p.Pro338His	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218437423C>A	UniProt
RCV000030732	p.Pro338His	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218437423C>A	ClinVar
rs745859904	p.Gly340Glu	missense variant	-	NC_000001.11:g.218437429G>A	ExAC,gnomAD
rs781013995	p.Gly340Arg	missense variant	-	NC_000001.11:g.218437428G>A	ExAC,gnomAD
RCV000210478	p.Tyr341Ter	frameshift	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218437432_218437436del	ClinVar
rs1553303357	p.Tyr341Ter	stop gained	-	NC_000001.11:g.218437433C>A	-
RCV000618984	p.Tyr341Ter	nonsense	-	NC_000001.11:g.218437433C>A	ClinVar
rs968289881	p.Asn342Ser	missense variant	-	NC_000001.11:g.218437435A>G	TOPMed
rs779554274	p.Ala343Thr	missense variant	-	NC_000001.11:g.218437437G>A	ExAC,TOPMed,gnomAD
rs748732392	p.Phe345Leu	missense variant	-	NC_000001.11:g.218437443T>C	ExAC,gnomAD
rs768326808	p.Phe345Leu	missense variant	-	NC_000001.11:g.218437445C>A	ExAC,TOPMed
rs1000597477	p.Ala349Thr	missense variant	-	NC_000001.11:g.218437455G>A	TOPMed
RCV000697705	p.Cys350Tyr	missense variant	Holt-Oram syndrome (HOS)	NC_000001.11:g.218437459G>A	ClinVar
rs773943154	p.Pro351Leu	missense variant	-	NC_000001.11:g.218437462C>T	ExAC,TOPMed,gnomAD
rs777045186	p.Leu353Val	missense variant	-	NC_000001.11:g.218437467T>G	ExAC,gnomAD
RCV000699164	p.Trp354Ter	nonsense	Holt-Oram syndrome (HOS)	NC_000001.11:g.218437472G>A	ClinVar
rs1373261825	p.Ser355Asn	missense variant	-	NC_000001.11:g.218437474G>A	TOPMed
COSM1338914	p.Ser356Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218437476T>G	NCI-TCGA Cosmic
rs1423949415	p.Val363Leu	missense variant	-	NC_000001.11:g.218441204G>C	gnomAD
rs768202390	p.Tyr367His	missense variant	-	NC_000001.11:g.218441216T>C	ExAC,gnomAD
NCI-TCGA novel	p.Tyr367Ter	stop gained	-	NC_000001.11:g.218441218T>A	NCI-TCGA
rs1417916795	p.Asn368Asp	missense variant	-	NC_000001.11:g.218441219A>G	gnomAD
rs374045359	p.Thr369Ile	missense variant	-	NC_000001.11:g.218441223C>T	ESP
rs1335224039	p.Ile370Arg	missense variant	-	NC_000001.11:g.218441226T>G	gnomAD
rs1375241926	p.Asn371Tyr	missense variant	-	NC_000001.11:g.218441228A>T	gnomAD
rs577318480	p.Glu373Asp	missense variant	-	NC_000001.11:g.218441236A>C	1000Genomes,ExAC,gnomAD
rs201788738	p.Ala376Ser	missense variant	-	NC_000001.11:g.218441243G>T	TOPMed,gnomAD
rs201788738	p.Ala376Thr	missense variant	-	NC_000001.11:g.218441243G>A	TOPMed,gnomAD
COSM6061068	p.Cys379Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218441252T>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Cys379Ter	stop gained	-	NC_000001.11:g.218441254C>A	NCI-TCGA
rs1553303745	p.Cys380Phe	missense variant	-	NC_000001.11:g.218441256G>T	-
RCV000441929	p.Cys380Trp	missense variant	-	NC_000001.11:g.218441257C>G	ClinVar
RCV000617436	p.Cys380Phe	missense variant	-	NC_000001.11:g.218441256G>T	ClinVar
rs201129153	p.Cys380Trp	missense variant	-	NC_000001.11:g.218441257C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs376159002	p.Val381Met	missense variant	-	NC_000001.11:g.218441258G>A	ESP,ExAC,gnomAD
RCV000624548	p.Val381Met	missense variant	Inborn genetic diseases	NC_000001.11:g.218441258G>A	ClinVar
RCV000621154	p.Val381Met	missense variant	-	NC_000001.11:g.218441258G>A	ClinVar
rs1217563256	p.Ser382Phe	missense variant	-	NC_000001.11:g.218441262C>T	gnomAD
rs1411651558	p.Gln383Arg	missense variant	-	NC_000001.11:g.218441265A>G	TOPMed
NCI-TCGA novel	p.Asp384Tyr	missense variant	-	NC_000001.11:g.218441267G>T	NCI-TCGA
NCI-TCGA novel	p.Glu386Ter	stop gained	-	NC_000001.11:g.218441273G>T	NCI-TCGA
rs1167424381	p.Pro387Arg	missense variant	-	NC_000001.11:g.218441277C>G	TOPMed
rs776191174	p.Thr389Ile	missense variant	-	NC_000001.11:g.218441283C>T	ExAC,gnomAD
COSM1320474	p.Leu391Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218441288C>G	NCI-TCGA Cosmic
rs1218609815	p.Tyr392Cys	missense variant	-	NC_000001.11:g.218441292A>G	gnomAD
RCV000380797	p.Ile394Thr	missense variant	Loeys-Dietz syndrome (LDS)	NC_000001.11:g.218441298T>C	ClinVar
rs886045980	p.Ile394Thr	missense variant	-	NC_000001.11:g.218441298T>C	TOPMed,gnomAD
rs1190307366	p.Gly395Asp	missense variant	-	NC_000001.11:g.218441301G>A	gnomAD
NCI-TCGA novel	p.Gly395Val	missense variant	-	NC_000001.11:g.218441301G>T	NCI-TCGA
rs751650226	p.Lys396Gln	missense variant	-	NC_000001.11:g.218441303A>C	ExAC,gnomAD
COSM678488	p.Glu401Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218441318G>C	NCI-TCGA Cosmic
rs1447245776	p.Leu403Val	missense variant	-	NC_000001.11:g.218441324C>G	TOPMed
NCI-TCGA novel	p.Leu403Ile	missense variant	-	NC_000001.11:g.218441324C>A	NCI-TCGA
COSM904021	p.Met406Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000001.11:g.218441334T>C	NCI-TCGA Cosmic
NCI-TCGA novel	p.Met406Val	missense variant	-	NC_000001.11:g.218441333A>G	NCI-TCGA
rs1183873092	p.Ile407Val	missense variant	-	NC_000001.11:g.218441336A>G	TOPMed
rs750218692	p.Lys409Arg	missense variant	-	NC_000001.11:g.218441343A>G	ExAC,gnomAD
NCI-TCGA novel	p.Ser410Thr	missense variant	-	NC_000001.11:g.218441345T>A	NCI-TCGA
RCV000656710	p.Cys411Ser	missense variant	Loeys-Dietz syndrome 4 (LDS4)	NC_000001.11:g.218441349G>C	ClinVar
rs1553303761	p.Cys411Ser	missense variant	-	NC_000001.11:g.218441349G>C	-
rs869025532	p.Cys413Ser	missense variant	-	NC_000001.11:g.218441354T>A	-
RCV000208019	p.Cys413Ser	missense variant	Thoracic aortic aneurysm and aortic dissection (TAAD)	NC_000001.11:g.218441354T>A	ClinVar

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000768	Congenital Abnormality	group	BEFREE
C0001418	Adenocarcinoma	group	BEFREE
C0001576	Adnexal Diseases	group	LHGDN
C0002395	Alzheimer's Disease	disease	BEFREE
C0002448	Ameloblastoma	disease	BEFREE
C0002736	Amyotrophic Lateral Sclerosis	disease	BEFREE
C0003130	Anoxia	phenotype	LHGDN
C0003486	Aortic Aneurysm	disease	BEFREE
C0003493	Aortic Diseases	group	BEFREE
C0003504	Aortic Valve Insufficiency	disease	CTD_human;HPO
C0003706	Arachnodactyly	disease	HPO
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0003886	Arthrogryposis	disease	GENOMICS_ENGLAND
C0004096	Asthma	disease	BEFREE;LHGDN
C0004364	Autoimmune Diseases	group	CTD_human
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0005890	Body Height	phenotype	GWASCAT;GWASDB
C0005941	Bone Diseases, Developmental	group	CTD_human
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0007820	Cerebrovascular Disorders	group	GENOMICS_ENGLAND
C0008031	Chest Pain	phenotype	HPO
C0008311	Cholangitis	disease	CTD_human
C0008449	Congenital anomaly of cartilage	group	RGD
C0008479	Chondrosarcoma	disease	BEFREE;LHGDN
C0008925	Cleft Palate	disease	CTD_human
C0009324	Ulcerative Colitis	disease	BEFREE
C0010346	Crohn Disease	disease	BEFREE
C0010520	Cyanosis	phenotype	CTD_human
C0011881	Diabetic Nephropathy	disease	BEFREE
C0011882	Diabetic Neuropathies	group	RGD
C0013238	Dry Eye Syndromes	group	BEFREE
C0013312	Dupuytren Contracture	disease	BEFREE
C0013405	Dyspnea, Paroxysmal	disease	HPO
C0013720	Ehlers-Danlos Syndrome	disease	GENOMICS_ENGLAND
C0014070	Encephalomyelitis	disease	BEFREE
C0014175	Endometriosis	disease	BEFREE;CTD_human
C0015393	Eye Abnormalities	group	CTD_human
C0016045	fibroma	disease	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0016059	Fibrosis	phenotype	LHGDN
C0016202	Flatfoot	phenotype	HPO
C0016529	Forced expiratory volume function	phenotype	GWASCAT
C0017601	Glaucoma	disease	BEFREE;CTD_human
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;LHGDN
C0017665	Membranous glomerulonephritis	disease	BEFREE
C0018798	Congenital Heart Defects	group	BEFREE;CTD_human
C0018800	Cardiomegaly	phenotype	HPO
C0019158	Hepatitis	disease	BEFREE
C0019159	Hepatitis A	disease	BEFREE
C0019189	Hepatitis, Chronic	disease	BEFREE
C0019207	Hepatoma, Morris	disease	BEFREE
C0019294	Hernia, Inguinal	phenotype	HPO
C0020538	Hypertensive disease	group	HPO
C0021390	Inflammatory Bowel Diseases	group	BEFREE
C0022548	Keloid	phenotype	BEFREE
C0022578	Keratoconus	disease	BEFREE;LHGDN
C0022658	Kidney Diseases	group	BEFREE
C0022661	Kidney Failure, Chronic	disease	BEFREE
C0023212	Left-Sided Heart Failure	disease	HPO
C0024117	Chronic Obstructive Airway Disease	disease	GWASCAT
C0024141	Lupus Erythematosus, Systemic	disease	BEFREE
C0024441	Macular Holes	disease	BEFREE
C0024530	Malaria	disease	BEFREE
C0024534	Malaria, Cerebral	disease	BEFREE
C0024535	Malaria, Falciparum	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0024796	Marfan Syndrome	disease	BEFREE;CLINGEN
C0025149	Medulloblastoma	disease	BEFREE
C0025202	melanoma	disease	BEFREE
C0026267	Mitral Valve Prolapse Syndrome	disease	HPO
C0026769	Multiple Sclerosis	disease	BEFREE
C0026948	Mycosis Fungoides	group	BEFREE
C0027051	Myocardial Infarction	disease	RGD
C0027092	Myopia	disease	BEFREE
C0027149	Myxoma	disease	BEFREE
C0027430	Nasal Polyps	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027651	Neoplasms	group	BEFREE
C0027708	Nephroblastoma	disease	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0028880	Odontogenic Tumors	group	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029422	Osteochondrodysplasias	group	RGD
C0029463	Osteosarcoma	disease	BEFREE
C0030567	Parkinson Disease	disease	BEFREE
C0032460	Polycystic Ovary Syndrome	disease	BEFREE
C0033578	Prostatic Neoplasms	group	LHGDN
C0034069	Pulmonary Fibrosis	disease	BEFREE
C0035238	Congenital abnormality of respiratory system	group	CTD_human
C0036202	Sarcoidosis	disease	BEFREE
C0036421	Systemic Scleroderma	disease	BEFREE
C0036646	Age-related cataract	disease	BEFREE
C0037274	Dermatologic disorders	group	BEFREE
C0037932	Curvature of spine	phenotype	HPO
C0040021	Thromboangiitis Obliterans	disease	BEFREE
C0041956	Ureteral obstruction	phenotype	CTD_human
C0042063	Urogenital Abnormalities	group	CTD_human
C0085119	Foot Ulcer	disease	LHGDN
C0085413	Polycystic Kidney, Autosomal Dominant	disease	BEFREE
C0086543	Cataract	disease	BEFREE
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0151491	Congenital musculoskeletal anomalies	group	CTD_human
C0152451	Chronic glomerulonephritis	disease	BEFREE
C0153676	Secondary malignant neoplasm of lung	disease	BEFREE
C0153687	Secondary malignant neoplasm of skin	disease	BEFREE
C0155877	Allergic asthma	disease	BEFREE
C0156147	Crohn's disease of large bowel	disease	BEFREE
C0162534	Prion Diseases	group	BEFREE
C0162872	Aortic Aneurysm, Thoracic	disease	BEFREE;CTD_human;GENOMICS_ENGLAND
C0175697	Van der Woude syndrome	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206172	Diabetic Foot	disease	LHGDN
C0206178	Cytomegalovirus Retinitis	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	BEFREE
C0206762	Limb Deformities, Congenital	group	CTD_human
C0220996	Infantile scurvy	disease	BEFREE
C0231807	Dyspnea on exertion	phenotype	HPO
C0235833	Congenital diaphragmatic hernia	disease	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0239946	Fibrosis, Liver	disease	BEFREE
C0240635	Byzanthine arch palate	disease	HPO
C0241240	Tall stature	phenotype	HPO
C0242852	Proliferative vitreoretinopathy	disease	BEFREE
C0263401	Cutis marmorata	disease	HPO
C0264133	Acquired flat foot	phenotype	HPO
C0264885	Myxoid transformation of mitral valve	disease	BEFREE
C0265264	Holt-Oram syndrome	disease	CLINVAR
C0265338	Coffin-Siris syndrome	disease	BEFREE
C0266568	Persistent Hyperplastic Primary Vitreous	disease	BEFREE
C0267818	Bile duct proliferation	disease	BEFREE
C0268351	Cutis Laxa, Autosomal Recessive, Type I	disease	BEFREE
C0268731	Renal glomerular disease	group	BEFREE
C0269102	Endometrioma	disease	CTD_human
C0278484	Malignant neoplasm of colon stage IV	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0282612	Prostatic Intraepithelial Neoplasias	disease	BEFREE
C0314719	Dryness of eye	phenotype	BEFREE
C0334347	Eccrine spiradenoma	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE
C0339573	Glaucoma, Primary Open Angle	disease	BEFREE
C0340164	Lofgrens syndrome	disease	BEFREE
C0340630	Aortic Aneurysm, Thoracoabdominal	disease	CTD_human
C0340643	Dissection of aorta	disease	HPO
C0345050	Congenital aneurysm of ascending aorta	disease	GENOMICS_ENGLAND
C0345905	Intrahepatic Cholangiocarcinoma	disease	BEFREE
C0345967	Malignant mesothelioma	disease	CTD_human
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0376634	Craniofacial Abnormalities	group	CTD_human
C0392775	Cystic medial necrosis of aorta	disease	HPO
C0399440	Hereditary gingival fibromatosis	disease	BEFREE
C0423798	Increased tendency to bruise	phenotype	HPO
C0431122	Atypical meningioma	disease	BEFREE
C0455829	Waist Circumference	phenotype	GWASCAT
C0476089	Endometrial Carcinoma	disease	BEFREE
C0497247	Increase in blood pressure	phenotype	HPO
C0497406	Overweight	phenotype	BEFREE
C0520459	Necrotizing Enterocolitis	disease	BEFREE
C0521585	Gastrointestinal mucositis	disease	BEFREE
C0521707	Bilateral cataracts (disorder)	disease	BEFREE
C0524910	Hepatitis C, Chronic	disease	BEFREE
C0553982	Impaired left ventricular function	phenotype	HPO
C0555198	Malignant Glioma	disease	BEFREE
C0574143	Liver calculus	disease	BEFREE
C0578022	Finding of body mass index	phenotype	GWASCAT
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0677932	Progressive Neoplastic Disease	phenotype	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0700208	Acquired scoliosis	phenotype	HPO
C0752355	Myotonia Fluctuans (disorder)	disease	BEFREE
C0877430	Asthma chronic	disease	BEFREE
C1270972	Mild cognitive disorder	disease	BEFREE
C1298820	Aneurysm of aortic root	disease	BEFREE
C1305855	Body mass index	phenotype	GWASCAT
C1334699	Mesenchymal Cell Neoplasm	disease	BEFREE
C1368683	Epithelioma	disease	BEFREE
C1449563	Cardiomyopathy, Familial Idiopathic	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1519383	Smoking Behaviors	phenotype	GWASCAT
C1533161	Eccrine Poroma	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1836635	Loeys-Dietz Aortic Aneurysm Syndrome	disease	CTD_human;MGD
C1836653	Ascending aortic dissection	phenotype	HPO
C1837218	Cleft palate, isolated	disease	BEFREE;CTD_human
C1851712	Dural ectasia	phenotype	HPO
C1857299	RETINAL NONATTACHMENT, NONSYNDROMIC CONGENITAL	disease	BEFREE
C1859726	ARTERIAL TORTUOSITY SYNDROME	disease	BEFREE
C1860493	Abnormality of the sternum	phenotype	HPO
C1956346	Coronary Artery Disease	disease	HPO
C2145472	Urothelial Carcinoma	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE
C2243080	Intestinal necrosis	disease	BEFREE
C2316810	Chronic kidney disease stage 5	disease	BEFREE
C2697932	Loeys-Dietz Syndrome	disease	BEFREE;CLINVAR;CTD_human;MGD
C2717865	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	disease	BEFREE
C3279191	Arterial tortuosity	phenotype	HPO
C3494422	Retrognathia	phenotype	HPO
C3495801	Granulomatosis with polyangiitis	disease	BEFREE
C3539781	Progressive cGVHD	disease	BEFREE
C3553762	LOEYS-DIETZ SYNDROME 4	disease	CLINVAR;UNIPROT
C3553764	Joint hyperflexibility	phenotype	HPO
C3714756	Intellectual Disability	group	GENOMICS_ENGLAND
C3811653	Experimental Organism Basal Cell Carcinoma	phenotype	BEFREE
C3825201	Mitochondrial pathology	phenotype	BEFREE
C4021790	Abnormality of the skeletal system	phenotype	BEFREE
C4022878	Descending aortic dissection	disease	HPO
C4025845	Abnormality of the iris	phenotype	HPO
C4049938	Physical Activity Measurement	phenotype	GWASCAT
C4050407	Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis	disease	BEFREE
C4082937	Necrotizing enterocolitis in fetus OR newborn	disease	BEFREE
C4082974	Dupuytren's Disease	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0001540	amyloid-beta binding	IDA
GO:0005102	signaling receptor binding	IMP
GO:0005114	type II transforming growth factor beta receptor binding	IDA
GO:0005114	type II transforming growth factor beta receptor binding	IPI
GO:0005114	type II transforming growth factor beta receptor binding	IBA
GO:0005114	type II transforming growth factor beta receptor binding	IMP
GO:0005125	cytokine activity	IBA
GO:0005160	transforming growth factor beta receptor binding	IDA
GO:0005515	protein binding	IPI
GO:0008083	growth factor activity	IEA
GO:0034714	type III transforming growth factor beta receptor binding	IPI
GO:0034714	type III transforming growth factor beta receptor binding	IBA
GO:0034714	type III transforming growth factor beta receptor binding	IMP
GO:0042803	protein homodimerization activity	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000902	cell morphogenesis	IDA
GO:0001501	skeletal system development	ISS
GO:0001654	eye development	IDA
GO:0001666	response to hypoxia	IMP
GO:0001822	kidney development	ISS
GO:0001837	epithelial to mesenchymal transition	IDA
GO:0001837	epithelial to mesenchymal transition	TAS
GO:0001843	neural tube closure	ISS
GO:0001942	hair follicle development	ISS
GO:0001942	hair follicle development	IDA
GO:0002576	platelet degranulation	TAS
GO:0003007	heart morphogenesis	IDA
GO:0003148	outflow tract septum morphogenesis	ISS
GO:0003149	membranous septum morphogenesis	ISS
GO:0003179	heart valve morphogenesis	ISS
GO:0003181	atrioventricular valve morphogenesis	ISS
GO:0003184	pulmonary valve morphogenesis	ISS
GO:0003203	endocardial cushion morphogenesis	ISS
GO:0003215	cardiac right ventricle morphogenesis	ISS
GO:0003222	ventricular trabecula myocardium morphogenesis	ISS
GO:0003274	endocardial cushion fusion	ISS
GO:0003289	atrial septum primum morphogenesis	ISS
GO:0003407	neural retina development	ISS
GO:0006468	protein phosphorylation	IDA
GO:0007050	cell cycle arrest	IDA
GO:0007179	transforming growth factor beta receptor signaling pathway	IDA
GO:0007179	transforming growth factor beta receptor signaling pathway	IBA
GO:0007435	salivary gland morphogenesis	IEP
GO:0007507	heart development	IDA
GO:0008219	cell death	IDA
GO:0008284	positive regulation of cell population proliferation	IDA
GO:0008285	negative regulation of cell population proliferation	IDA
GO:0008347	glial cell migration	IDA
GO:0008584	male gonad development	ISS
GO:0009611	response to wounding	IEP
GO:0009792	embryo development ending in birth or egg hatching	TAS
GO:0010002	cardioblast differentiation	IDA
GO:0010629	negative regulation of gene expression	IDA
GO:0010634	positive regulation of epithelial cell migration	IDA
GO:0010693	negative regulation of alkaline phosphatase activity	IDA
GO:0010718	positive regulation of epithelial to mesenchymal transition	IDA
GO:0010862	positive regulation of pathway-restricted SMAD protein phosphorylation	IBA
GO:0010936	negative regulation of macrophage cytokine production	IDA
GO:0014068	positive regulation of phosphatidylinositol 3-kinase signaling	IDA
GO:0016477	cell migration	IDA
GO:0016525	negative regulation of angiogenesis	IDA
GO:0030097	hemopoiesis	ISS
GO:0030199	collagen fibril organization	IDA
GO:0030307	positive regulation of cell growth	IDA
GO:0030308	negative regulation of cell growth	IDA
GO:0030326	embryonic limb morphogenesis	ISS
GO:0030509	BMP signaling pathway	IBA
GO:0030593	neutrophil chemotaxis	ISS
GO:0031069	hair follicle morphogenesis	ISS
GO:0032147	activation of protein kinase activity	IDA
GO:0032570	response to progesterone	IDA
GO:0032874	positive regulation of stress-activated MAPK cascade	IDA
GO:0032909	regulation of transforming growth factor beta2 production	IMP
GO:0033630	positive regulation of cell adhesion mediated by integrin	IDA
GO:0035910	ascending aorta morphogenesis	ISS
GO:0042060	wound healing	ISS
GO:0042127	regulation of cell population proliferation	IBA
GO:0042416	dopamine biosynthetic process	ISS
GO:0042476	odontogenesis	NAS
GO:0042493	response to drug	IDA
GO:0042704	uterine wall breakdown	TAS
GO:0043525	positive regulation of neuron apoptotic process	IDA
GO:0045216	cell-cell junction organization	IDA
GO:0045726	positive regulation of integrin biosynthetic process	IDA
GO:0045747	positive regulation of Notch signaling pathway	IDA
GO:0045778	positive regulation of ossification	IEP
GO:0045787	positive regulation of cell cycle	ISS
GO:0045823	positive regulation of heart contraction	IDA
GO:0046580	negative regulation of Ras protein signal transduction	ISS
GO:0048103	somatic stem cell division	ISS
GO:0048566	embryonic digestive tract development	IEP
GO:0048666	neuron development	ISS
GO:0048699	generation of neurons	TAS
GO:0048839	inner ear development	ISS
GO:0050680	negative regulation of epithelial cell proliferation	IMP
GO:0050680	negative regulation of epithelial cell proliferation	IDA
GO:0050714	positive regulation of protein secretion	IDA
GO:0050778	positive regulation of immune response	ISS
GO:0051781	positive regulation of cell division	IEA
GO:0051794	regulation of timing of catagen	IDA
GO:0051795	positive regulation of timing of catagen	IDA
GO:0051891	positive regulation of cardioblast differentiation	IDA
GO:0060038	cardiac muscle cell proliferation	IDA
GO:0060065	uterus development	ISS
GO:0060317	cardiac epithelial to mesenchymal transition	IDA
GO:0060389	pathway-restricted SMAD protein phosphorylation	IDA
GO:0060395	SMAD protein signal transduction	IDA
GO:0060395	SMAD protein signal transduction	IBA
GO:0060412	ventricular septum morphogenesis	ISS
GO:0060413	atrial septum morphogenesis	ISS
GO:0061626	pharyngeal arch artery morphogenesis	ISS
GO:0062009	secondary palate development	ISS
GO:0097191	extrinsic apoptotic signaling pathway	IDA
GO:1902256	regulation of apoptotic process involved in outflow tract morphogenesis	ISS
GO:1902895	positive regulation of pri-miRNA transcription by RNA polymerase II	IDA
GO:1903701	substantia propria of cornea development	ISS
GO:1904888	cranial skeletal system development	ISS
GO:1905006	negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation	ISS
GO:1905007	positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation	ISS
GO:1903659	regulation of complement-dependent cytotoxicity	IMP

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	IDA
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IBA
GO:0005615	extracellular space	IDA
GO:0030424	axon	ISS
GO:0031093	platelet alpha granule lumen	TAS
GO:0043025	neuronal cell body	ISS
GO:0062023	collagen-containing extracellular matrix	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-114608	Platelet degranulation	TAS
R-HSA-1474244	Extracellular matrix organization	TAS
R-HSA-1474244	Extracellular matrix organization	IEA
R-HSA-1566948	Elastic fibre formation	TAS
R-HSA-2129379	Molecules associated with elastic fibres	TAS
R-HSA-3000178	ECM proteoglycans	IEA
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76005	Response to elevated platelet cytosolic Ca2+	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C006718	1,12-benzoperylene	1,12-benzoperylene results in increased expression of TGFB2 mRNA	26377693
D015056	1-Methyl-3-isobutylxanthine	[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA	16997883
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]	26114860
D015655	1-Methyl-4-phenylpyridinium	Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]]	26114860
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA	24633426; 26921287; 28049044;
D015058	1-Naphthylisothiocyanate	FGG protein affects the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	26921287
D015058	1-Naphthylisothiocyanate	FGG protein affects the reaction [leukadherin-1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]]	26921287
D015058	1-Naphthylisothiocyanate	IFNG protein affects the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	26921287
D015058	1-Naphthylisothiocyanate	leukadherin-1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	26921287
D015058	1-Naphthylisothiocyanate	RAG1 gene mutant form inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	28049044
D015058	1-Naphthylisothiocyanate	Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	24633426
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA	23558518
C581572	1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea	1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea results in increased expression of TGFB2 mRNA	25827057
C581572	1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea	[Carbon Tetrachloride co-treated with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea] results in increased expression of TGFB2 mRNA	25827057
C548651	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester	2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in decreased expression of TGFB2 mRNA	19933214
C404910	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of TGFB2 mRNA]	19414516
C029497	2,3-bis(3'-hydroxybenzyl)butyrolactone	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFB2 mRNA	19167446
C013186	2,3-pentanedione	2,3-pentanedione results in increased expression of TGFB2 mRNA	25710175
C029955	2-nitrotoluene	2-nitrotoluene results in decreased expression of TGFB2 mRNA	16460773
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of TGFB2 mRNA	23196670
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
C105260	4-tert-octylphenol	4-tert-octylphenol results in decreased expression of TGFB2 protein	18065773
C553817	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one	7-(benzylamino)-1,3,4,8-tetrahydropyrrolo(4,3,2-de)quinolin-8(1H)-one results in increased expression of TGFB2 mRNA	19936915
D015124	8-Bromo Cyclic Adenosine Monophosphate	[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA	16997883
D000079	Acetaldehyde	Acetaldehyde affects the expression of TGFB2 mRNA	22634333
D000082	Acetaminophen	Acetaminophen results in increased expression of TGFB2 mRNA	29067470
D020106	Acrylamide	Acrylamide results in decreased expression of TGFB2 mRNA	28959563
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of TGFB2 mRNA	27153756
D000393	Air Pollutants	Air Pollutants analog results in decreased expression of TGFB2 mRNA	21757418
D000499	Allylamine	Allylamine results in increased expression of TGFB2 mRNA	23558518
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of TGFB2 mRNA	16483693
D000942	Antigens, Bacterial	[MYD88 gene mutant form affects the susceptibility to [Antigens, Bacterial co-treated with Ovalbumin]] which affects the expression of TGFB2 mRNA	29067999
C015001	arsenite	arsenite results in decreased expression of TGFB2 mRNA	16085347; 23974009;
C015001	arsenite	caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TGFB2 mRNA]	16085347
C015001	arsenite	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of TGFB2 mRNA	15894712
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]	26354774
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]	26354774
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein results in increased localization of MAPK7 protein]	25145660
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein results in increased localization of SMAD2 protein]	25145660
C015001	arsenite	arsenite inhibits the reaction [TGFB2 protein results in increased localization of SMAD3 protein]	25145660
C015001	arsenite	arsenite results in decreased expression of TGFB2 mRNA	15894712
C015001	arsenite	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C015001	arsenite	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
C015001	arsenite	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C015001	arsenite	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of TGFB2 mRNA	15305145
D016589	Astemizole	Astemizole results in increased expression of TGFB2 mRNA	20221588
D001280	Atrazine	Atrazine results in decreased expression of TGFB2 mRNA	25929836
C547126	AZM551248	AZM551248 results in increased expression of TGFB2 mRNA	22323515
C487081	belinostat	belinostat results in increased expression of TGFB2 mRNA	23671600
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TGFB2 mRNA	19181443; 20106945;
D001564	Benzo(a)pyrene	AHR protein promotes the reaction [Benzo(a)pyrene results in decreased expression of TGFB2 mRNA]	15034205
D001564	Benzo(a)pyrene	[arsenite co-treated with Benzo(a)pyrene] results in decreased expression of TGFB2 mRNA	15894712
D001564	Benzo(a)pyrene	Benzo(a)pyrene affects the expression of TGFB2 mRNA	15037607
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of TGFB2 mRNA	15034205; 15894712; 19770486; 21569818; 21715664;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of TGFB2 mRNA	22228805
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in decreased expression of TGFB2 mRNA	26377693
D001622	Betaine	Betaine results in increased expression of TGFB2 mRNA	26391144
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of TGFB2 mRNA	30951980
C006780	bisphenol A	bisphenol A results in increased expression of TGFB2 mRNA	30248606
C006780	bisphenol A	bisphenol A affects the expression of TGFB2 mRNA	20170705
C006780	bisphenol A	bisphenol A results in decreased expression of TGFB2 mRNA	16029874; 16474171; 19371625;
C006780	bisphenol A	[bisphenol A co-treated with Tretinoin] results in decreased expression of TGFB2 mRNA	30951980
C006780	bisphenol A	bisphenol A results in decreased methylation of TGFB2 promoter	27312807
C006780	bisphenol A	bisphenol A results in increased expression of TGFB2 mRNA	30951980
C006780	bisphenol A	bisphenol A affects the expression of TGFB2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in decreased expression of TGFB2 mRNA	30816183
C000611646	bisphenol F	[bisphenol F co-treated with Tretinoin] results in decreased expression of TGFB2 mRNA	30951980
C000611646	bisphenol F	bisphenol F results in increased expression of TGFB2 mRNA	30951980
D001761	Bleomycin	[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
D001761	Bleomycin	[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
D001761	Bleomycin	[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
C546611	brevetoxin 2	brevetoxin 2 results in increased expression of TGFB2 mRNA	20498034
C099813	bromochloroacetic acid	bromochloroacetic acid results in decreased expression of TGFB2 mRNA	16460773
D002083	Butylated Hydroxyanisole	[propylparaben co-treated with Butylated Hydroxyanisole] results in increased expression of TGFB2 mRNA	25086368
D019256	Cadmium Chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA	12634122
C055494	caffeic acid phenethyl ester	caffeic acid phenethyl ester inhibits the reaction [arsenite results in decreased expression of TGFB2 mRNA]	16085347
D002117	Calcitriol	Calcitriol results in increased expression of TGFB2 mRNA	16002434; 21592394; 26485663;
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of TGFB2 mRNA	21592394
D002211	Capsaicin	Capsaicin results in increased expression of TGFB2 protein	22150557
D002211	Capsaicin	[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D002211	Capsaicin	Naproxen inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D002211	Capsaicin	Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D002220	Carbamazepine	Carbamazepine affects the expression of TGFB2 mRNA	22634333
D012721	Carbaryl	Carbaryl results in increased expression of TGFB2 mRNA	27829164
D002235	Carbofuran	Carbofuran results in increased expression of TGFB2 mRNA	20211217
D002251	Carbon Tetrachloride	Carbon Tetrachloride affects the expression of TGFB2 mRNA	17484886
D002251	Carbon Tetrachloride	[Carbon Tetrachloride co-treated with 1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea] results in increased expression of TGFB2 mRNA	25827057
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of TGFB2 mRNA	15056808; 25827057; 26921287; 28527913;
D002251	Carbon Tetrachloride	VWF gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB2 mRNA]	28527913
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of TGFB2 mRNA	16644059; 23558518;
D002725	Chloroform	Chloroform results in increased expression of TGFB2 mRNA	23558518
D002737	Chloroprene	Chloroprene results in decreased expression of TGFB2 mRNA	23125180
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of TGFB2 mRNA	20350560
D002762	Cholecalciferol	Cholecalciferol results in increased expression of TGFB2 mRNA	17170073
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB2 mRNA	22915297
D002794	Choline	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB2 mRNA]	22915297
C023600	chromic oxide	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA	12634122
C017133	chromous chloride	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA	12634122
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of TGFB2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of TGFB2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of TGFB2 mRNA	21151649
C007095	cobaltiprotoporphyrin	cobaltiprotoporphyrin inhibits the reaction [IL1B protein results in decreased secretion of TGFB2 protein]	21954917
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of TGFB2 mRNA	26314263
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of TGFB2 mRNA	24386269
D003042	Cocaine	Cocaine results in increased expression of TGFB2 mRNA	17898221
D003300	Copper	Copper deficiency results in increased expression of TGFB2 mRNA	26033743
D003375	Coumestrol	[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFB2 mRNA	19167446
D003375	Coumestrol	[Coumestrol co-treated with Resveratrol] results in decreased expression of TGFB2 mRNA	19167446
D003375	Coumestrol	Coumestrol results in decreased expression of TGFB2 mRNA	19167446
C030973	cupric oxide	cupric oxide results in decreased expression of TGFB2 mRNA	22077320
D003471	Cuprizone	Cuprizone results in increased expression of TGFB2 mRNA	26577399
C057862	cyanoginosin LR	cyanoginosin LR results in increased expression of TGFB2 mRNA	17654400
D003520	Cyclophosphamide	Cyclophosphamide results in increased expression of TGFB2 mRNA	23558518
D016572	Cyclosporine	Cyclosporine results in decreased expression of TGFB2 mRNA	27989131
D016572	Cyclosporine	Cyclosporine results in increased expression of TGFB2 mRNA	23558518
C089595	cylindrospermopsin	cylindrospermopsin results in increased expression of TGFB2 mRNA	23726867
D003545	Cysteine	Cysteine inhibits the reaction [Thioacetamide results in increased expression of TGFB2 mRNA]	15158331
D003609	Dactinomycin	Dactinomycin inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]	18253093
D003609	Dactinomycin	Dactinomycin inhibits the reaction [TGFB2 protein results in increased expression of FN1 mRNA]	18253093
C515055	darinaparsin	darinaparsin results in increased expression of TGFB2 mRNA	22535156
D000069439	Dasatinib	Dasatinib results in increased expression of TGFB2 mRNA	20579391
D003907	Dexamethasone	[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA	16997883
D003907	Dexamethasone	Dexamethasone results in decreased expression of TGFB2 mRNA	16997883
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of TGFB2 mRNA	21266533
D004008	Diclofenac	Diclofenac results in decreased expression of TGFB2 mRNA	17379860
C027118	didecyldimethylammonium	didecyldimethylammonium results in decreased expression of TGFB2 mRNA	23537712
D004041	Dietary Fats	[Dietary Fats co-treated with Dietary Sucrose] results in increased expression of TGFB2 protein	26042203
D004041	Dietary Fats	Dietary Fats results in increased expression of TGFB2 mRNA	18042831
D004041	Dietary Fats	[Dietary Fats co-treated with Resveratrol] results in increased expression of TGFB2 mRNA	21852083
D019422	Dietary Sucrose	[Dietary Fats co-treated with Dietary Sucrose] results in increased expression of TGFB2 protein	26042203
D019422	Dietary Sucrose	Dietary Sucrose results in increased expression of TGFB2 mRNA	26033743
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of TGFB2 mRNA	20920545
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of TGFB2 protein	20920545
C058705	diethyl malate	diethyl malate affects the expression of TGFB2 mRNA	24814887
C058705	diethyl malate	S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of TGFB2 mRNA]	24814887
D004052	Diethylnitrosamine	AHR protein inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB2 mRNA]	19996281
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of TGFB2 mRNA	18282651; 19996281; 24535843;
D004052	Diethylnitrosamine	TGFB2 gene mutant form results in increased susceptibility to Diethylnitrosamine	11559531
D004052	Diethylnitrosamine	TGFB2 gene mutant form results in increased susceptibility to [Diethylnitrosamine co-treated with Phenobarbital]	11526486
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of TGFB2 mRNA	23830814
D013196	Dihydrotestosterone	Dihydrotestosterone results in increased expression of TGFB2 mRNA	29581250
C472511	dimethylarsinous acid	dimethylarsinous acid results in increased expression of TGFB2 mRNA	19945496; 20886546;
D015232	Dinoprostone	[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
D015232	Dinoprostone	[HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
D015232	Dinoprostone	[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]	28434932
D004221	Disulfiram	Disulfiram affects the expression of TGFB2 mRNA	19088833
D004280	Dobutamine	Dobutamine results in increased expression of TGFB2 mRNA	16760913
D000077265	Donepezil	Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]]	26114860
D004298	Dopamine	Dopamine results in increased expression of TGFB2 mRNA	16760913
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
D004317	Doxorubicin	Doxorubicin results in increased expression of TGFB2 mRNA	20211217; 23558518;
D013759	Dronabinol	Dronabinol promotes the reaction [Estradiol results in increased expression of TGFB2 mRNA]	8390853
D004365	Drugs, Chinese Herbal	Drugs, Chinese Herbal results in decreased expression of TGFB2 mRNA	29667321
D004656	Enalapril	Enalapril results in decreased expression of TGFB2 mRNA	17164399
D004726	Endosulfan	Endosulfan results in decreased expression of TGFB2 mRNA	30090376
D004726	Endosulfan	Endosulfan results in decreased expression of TGFB2 mRNA	29391264
D020536	Enzyme Activators	[Enzyme Activators results in increased activity of SIRT1 protein] inhibits the reaction [TGFB2 protein results in increased expression of ACTA2 mRNA]	25707573
D020536	Enzyme Activators	[Enzyme Activators results in increased activity of SIRT1 protein] inhibits the reaction [TGFB2 protein results in increased expression of ACTA2 protein]	25707573
D020536	Enzyme Activators	[Enzyme Activators results in increased activity of SIRT1 protein] inhibits the reaction [TGFB2 protein results in increased expression of EP300 protein]	25707573
D004958	Estradiol	EGF protein inhibits the reaction [Estradiol results in decreased expression of TGFB2 mRNA]	24758408
D004958	Estradiol	Estradiol affects the expression of TGFB2 mRNA	14699072
D004958	Estradiol	[Estradiol binds to ESR2 protein] which results in decreased expression of TGFB2 mRNA	20404318
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of TGFB2 mRNA	20660070
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of TGFB2 mRNA	19619570
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of TGFB2 mRNA	30165855
D004958	Estradiol	Estradiol results in decreased expression of TGFB2 mRNA	16474171; 19167446; 19619570; 24758408; 25321415;
D004958	Estradiol	Estradiol results in increased expression of TGFB2 mRNA	11813992; 19484750;
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in decreased expression of TGFB2 mRNA	17404688
D004958	Estradiol	[Raloxifene Hydrochloride co-treated with Estradiol] results in increased expression of TGFB2 mRNA	21185374
D004958	Estradiol	Dronabinol promotes the reaction [Estradiol results in increased expression of TGFB2 mRNA]	8390853
D004958	Estradiol	Estradiol affects the expression of TGFB2 mRNA	15598610
D004958	Estradiol	Estradiol results in increased expression of TGFB2 mRNA	19484750; 8390853;
D004958	Estradiol	Estradiol results in decreased expression of TGFB2 mRNA	20068009
D000431	Ethanol	Ethanol results in increased expression of TGFB2 mRNA	30319688
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of TGFB2 mRNA	20170705
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of TGFB2 mRNA	18936297
D005230	Fatty Acids, Nonesterified	Fatty Acids, Nonesterified affects the expression of TGFB2 mRNA	30402207
D005230	Fatty Acids, Nonesterified	MIR26A1 mRNA inhibits the reaction [Fatty Acids, Nonesterified affects the expression of TGFB2 mRNA]	30402207
C001209	fenamic acid	fenamic acid results in increased expression of TGFB2 mRNA	23558518
C540355	fenamidone	fenamidone results in increased expression of TGFB2 mRNA	27029645
C020326	ferric nitrilotriacetate	ferric nitrilotriacetate results in increased expression of TGFB2 mRNA	23208426
C082360	fipronil	fipronil results in increased methylation of TGFB2 gene	28536466
D005472	Fluorouracil	TGFB2 protein affects the susceptibility to Fluorouracil	16217747
D005472	Fluorouracil	TGFB2 gene polymorphism results in decreased susceptibility to Fluorouracil	18941179
C061365	flusilazole	flusilazole affects the expression of TGFB2 mRNA	22634333
D005620	Freund's Adjuvant	Freund's Adjuvant inhibits the reaction [Urethane results in decreased expression of TGFB2 mRNA]	12810352
D005620	Freund's Adjuvant	Freund's Adjuvant results in increased expression of and results in increased secretion of TGFB2 protein	30025850
D005620	Freund's Adjuvant	Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of and results in increased secretion of TGFB2 protein]	30025850
D005632	Fructose	[FGF21 gene mutant form results in increased susceptibility to Fructose] which results in increased expression of TGFB2 mRNA	28123933
C039281	furan	furan results in decreased expression of TGFB2 mRNA	26194646
D005665	Furosemide	Furosemide results in increased expression of TGFB2 mRNA	16526316
C001277	geldanamycin	geldanamycin results in increased expression of TGFB2 mRNA	26705709
C056507	gemcitabine	gemcitabine results in increased expression of TGFB2 mRNA	17039268
D019833	Genistein	Genistein results in decreased expression of TGFB2 mRNA	16474171; 22228119;
D005839	Gentamicins	Gentamicins results in increased expression of TGFB2 mRNA	22061828
D006820	Hyaluronic Acid	MAP3K3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]	20633555
D006820	Hyaluronic Acid	MAPK1 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]	20633555
D006820	Hyaluronic Acid	MAPK3 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]	20633555
D006820	Hyaluronic Acid	MAPK7 protein promotes the reaction [TGFB2 protein results in increased abundance of Hyaluronic Acid]	20633555
D006820	Hyaluronic Acid	TGFB2 protein results in increased abundance of Hyaluronic Acid	20633555
D006861	Hydrogen Peroxide	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2 protein] results in increased expression of BCL2 mRNA	20606027
D006861	Hydrogen Peroxide	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of BCL2 protein	20606027
D006861	Hydrogen Peroxide	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of XIAP mRNA	20606027
D006861	Hydrogen Peroxide	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of XIAP protein	20606027
C474021	indirubin-3'-monoxime	indirubin-3'-monoxime results in increased expression of TGFB2 protein	21948866
C474021	indirubin-3'-monoxime	Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein]	21948866
C016517	indole-3-carbinol	indole-3-carbinol results in increased expression of TGFB2 mRNA	21948866
C016517	indole-3-carbinol	Lipopolysaccharides affects the susceptibility to [indole-3-carbinol results in increased expression of TGFB2 mRNA]	21948866
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFB2 mRNA	25613284
D007545	Isoproterenol	Isoproterenol results in increased expression of TGFB2 mRNA	20211217; 23558518;
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of TGFB2 mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of TGFB2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of TGFB2 mRNA	24796395; 26752646;
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of TGFB2 mRNA	26644586
D007854	Lead	Lead affects the expression of TGFB2 mRNA	28903495
C008261	lead acetate	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA	12634122
C038753	leptomycin B	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C038753	leptomycin B	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
C000589733	leukadherin-1	FGG protein affects the reaction [leukadherin-1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]]	26921287
C000589733	leukadherin-1	leukadherin-1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	26921287
C440499	lipopolysaccharide, Escherichia coli O111 B4	lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of TGFB2 mRNA	29879404
D008070	Lipopolysaccharides	Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein]	21948866
D008070	Lipopolysaccharides	Lipopolysaccharides affects the susceptibility to [indole-3-carbinol results in increased expression of TGFB2 mRNA]	21948866
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of TGFB2 mRNA	21131560
C025340	manganese chloride	manganese chloride results in increased expression of TGFB2 mRNA	28801915
D008628	Mercury	Mercury results in increased expression of TGFB2 mRNA	16823088
D009921	Metaproterenol	Metaproterenol results in increased expression of TGFB2 mRNA	23558518
D008701	Methapyrilene	Methapyrilene results in increased expression of TGFB2 mRNA	23558518
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB2 mRNA	22915297
D008715	Methionine	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB2 mRNA]	22915297
D008715	Methionine	Methionine inhibits the reaction [Thioacetamide results in increased expression of TGFB2 mRNA]	15158331
D008727	Methotrexate	Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of and results in increased secretion of TGFB2 protein]	30025850
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of TGFB2 mRNA	28001369
D008767	Methylmercury Compounds	Methylmercury Compounds results in increased expression of TGFB2 mRNA	21664453
C008493	methylselenic acid	methylselenic acid results in increased expression of TGFB2 mRNA	18548127
D015735	Mifepristone	Mifepristone results in decreased expression of TGFB2 mRNA	25972201
D008911	Minocycline	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2 protein] results in increased expression of BCL2 mRNA	20606027
D008911	Minocycline	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of BCL2 protein	20606027
D008911	Minocycline	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of XIAP mRNA	20606027
D008911	Minocycline	[Minocycline co-treated with Hydrogen Peroxide co-treated with TGFB2] results in increased expression of XIAP protein	20606027
D008942	Mitoxantrone	Mitoxantrone results in increased expression of TGFB2 mRNA	23558518
C000622638	MLN7243	MLN7243 results in increased sumoylation of TGFB2 protein	31285264
C406082	monomethylarsonous acid	monomethylarsonous acid results in increased expression of TGFB2 mRNA	19945496
C406082	monomethylarsonous acid	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C406082	monomethylarsonous acid	leptomycin B inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]	26354774
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein results in increased localization of MAPK7 protein]	25145660
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein results in increased localization of SMAD2 protein]	25145660
C406082	monomethylarsonous acid	monomethylarsonous acid inhibits the reaction [TGFB2 protein results in increased localization of SMAD3 protein]	25145660
C406082	monomethylarsonous acid	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
C406082	monomethylarsonous acid	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
C500085	muraglitazar	muraglitazar results in increased expression of TGFB2 mRNA	21515302
D009151	Mustard Gas	Mustard Gas results in decreased expression of TGFB2 mRNA	18955075
D009288	Naproxen	[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D009288	Naproxen	Naproxen inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D009355	Neomycin	Neomycin results in increased expression of TGFB2 mRNA	30626089
D009355	Neomycin	Plant Oils inhibits the reaction [Neomycin results in increased expression of TGFB2 mRNA]	30626089
D009536	Niacinamide	Niacinamide inhibits the reaction [Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]	25707573
D009536	Niacinamide	Niacinamide inhibits the reaction [Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]	25707573
D009532	Nickel	Nickel results in decreased expression of TGFB2 mRNA	24768652; 25583101;
D009582	Nitrofurantoin	Nitrofurantoin results in increased expression of TGFB2 mRNA	23558518
D009638	Norepinephrine	Norepinephrine results in increased expression of TGFB2 mRNA	15326086
D009638	Norepinephrine	Norepinephrine results in increased expression of TGFB2 protein	15326086
D009638	Norepinephrine	Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA]	15326086
C464660	obeticholic acid	obeticholic acid results in decreased expression of TGFB2 mRNA	27939613
C025589	ochratoxin A	ochratoxin A metabolite results in increased expression of TGFB2 mRNA	26314263
C025589	ochratoxin A	ochratoxin A results in increased expression of TGFB2 mRNA	26314263
C025589	ochratoxin A	NFE2L2 protein affects the reaction [ochratoxin A results in decreased expression of TGFB2 mRNA]	28710020
C025589	ochratoxin A	ochratoxin A results in decreased expression of TGFB2 mRNA	28710020
C025589	ochratoxin A	ochratoxin A results in increased expression of TGFB2 mRNA	28710020
C025589	ochratoxin A	ochratoxin A results in increased expression of TGFB2 mRNA	23208426; 23358140;
D019301	Oleic Acid	[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA	30547786
C016340	o,p'-DDT	o,p'-DDT results in decreased expression of TGFB2 mRNA	19371625
D010042	Ouabain	Ouabain results in decreased expression of TGFB2 mRNA	28795476
D010047	Ovalbumin	[MYD88 gene mutant form affects the susceptibility to [Antigens, Bacterial co-treated with Ovalbumin]] which affects the expression of TGFB2 mRNA	29067999
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in increased expression of TGFB2 mRNA	25729387
D010100	Oxygen	Oxygen deficiency results in increased expression of TGFB2 mRNA	21531777
D010100	Oxygen	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of TGFB2 mRNA]	21531777
D010126	Ozone	Ozone results in increased expression of TGFB2 mRNA	31476115
D019308	Palmitic Acid	[Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of TGFB2 mRNA	30547786
D000073878	Palm Oil	Palm Oil results in increased expression of TGFB2 mRNA	18042831
D010269	Paraquat	Paraquat affects the expression of TGFB2 mRNA	16854511
D010634	Phenobarbital	TGFB2 gene mutant form results in increased susceptibility to [Diethylnitrosamine co-treated with Phenobarbital]	11526486
D010653	Phenylbutazone	Phenylbutazone results in increased expression of TGFB2 mRNA	23558518
D010656	Phenylephrine	Phenylephrine results in increased expression of TGFB2 mRNA	19443575
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
D010672	Phenytoin	Phenytoin results in decreased expression of TGFB2 mRNA	9118846
C006253	pirinixic acid	[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of TGFB2 mRNA	19710929
D010938	Plant Oils	Plant Oils inhibits the reaction [Neomycin results in increased expression of TGFB2 mRNA]	30626089
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls affects the expression of TGFB2 mRNA	21334430
D011078	Polychlorinated Biphenyls	Polychlorinated Biphenyls analog results in decreased expression of TGFB2 mRNA	16474171
C060540	polyhexamethyleneguanidine	polyhexamethyleneguanidine results in increased expression of TGFB2 mRNA	24583197
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of TGFB2 mRNA	22714537
D011224	Prazosin	Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA]	15326086
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of TGFB2 mRNA	20660070
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in decreased expression of TGFB2 mRNA	17404688
D011374	Progesterone	Progesterone results in decreased expression of TGFB2	17510236
C005556	propionaldehyde	propionaldehyde results in increased expression of TGFB2 mRNA	26079696
C006068	propylparaben	[propylparaben co-treated with Butylated Hydroxyanisole] results in increased expression of TGFB2 mRNA	25086368
D011441	Propylthiouracil	Propylthiouracil results in increased expression of TGFB2 mRNA	24780913
D011441	Propylthiouracil	[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of TGFB2 mRNA	31068541
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of TGFB2 mRNA	27029645
C014175	pyrazolo(3,4-d)pyrimidine	pyrazolo(3,4-d)pyrimidine analog affects the expression of TGFB2 mRNA	21152443
D011794	Quercetin	Quercetin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB2 mRNA]	22915297
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of TGFB2 mRNA	29458080
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride affects the expression of TGFB2 mRNA	14699072
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with ESR2 protein] results in increased expression of TGFB2 mRNA	19059307
D020849	Raloxifene Hydrochloride	[Raloxifene Hydrochloride co-treated with Estradiol] results in increased expression of TGFB2 mRNA	21185374
D000077185	Resveratrol	[Coumestrol co-treated with Resveratrol] results in decreased expression of TGFB2 mRNA	19167446
D000077185	Resveratrol	Niacinamide inhibits the reaction [Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]	25707573
D000077185	Resveratrol	Niacinamide inhibits the reaction [Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein promotes the reaction [EP300 protein binds to COL1A2 promoter]]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of ACTA2 mRNA]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of ACTA2 protein]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of EP300 protein]	25707573
D000077185	Resveratrol	Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of FN1 mRNA alternative form]	25707573
D000077185	Resveratrol	Resveratrol results in decreased expression of TGFB2 mRNA	19371625
D000077185	Resveratrol	Resveratrol results in increased expression of TGFB2 mRNA	12002526
D000077185	Resveratrol	SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [TGFB2 protein results in increased expression of FN1 mRNA alternative form]]	25707573
D000077185	Resveratrol	[Dietary Fats co-treated with Resveratrol] results in increased expression of TGFB2 mRNA	21852083
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of TGFB2 mRNA]	21531777
D000077154	Rosiglitazone	Rosiglitazone results in decreased expression of TGFB2 mRNA	21531777
D012402	Rotenone	Rotenone results in increased expression of TGFB2 mRNA	23186747
C093642	SB 203580	SB 203580 inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]	18253093
C093642	SB 203580	SB 203580 inhibits the reaction [TGFB2 protein results in increased phosphorylation of SMAD3 protein]	18253093
C042431	S-ethyl glutathione	S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of TGFB2 mRNA]	24814887
D012834	Silver	Silver results in decreased expression of TGFB2 mRNA	27131904
D012906	Smoke	Smoke results in increased expression of TGFB2 mRNA	21095227
C009277	sodium arsenate	sodium arsenate results in decreased expression of TGFB2 mRNA	21795629
C009277	sodium arsenate	sodium arsenate results in increased expression of TGFB2 mRNA	21795629
C017947	sodium arsenite	[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of TGFB2 mRNA	12634122
C017947	sodium arsenite	sodium arsenite results in decreased expression of TGFB2 mRNA	20886546; 22199297; 22714537;
C017947	sodium arsenite	sodium arsenite results in increased expression of TGFB2 mRNA	12634122; 29301061;
C017947	sodium arsenite	sodium arsenite inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	23732083
C017947	sodium arsenite	sodium arsenite inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD3 protein]	23732083
C017947	sodium arsenite	sodium arsenite results in decreased expression of TGFB2 mRNA	23732083
D012965	Sodium Chloride	Sodium Chloride results in increased expression of TGFB2 mRNA	26800359
C025399	sodium tungstate(VI)	sodium tungstate(VI) affects the expression of TGFB2 mRNA	26164860
C060506	sphingosine 1-phosphate	TGFB2 protein promotes the reaction [SPNS2 protein results in increased secretion of sphingosine 1-phosphate]	29772789
C525422	SRT1720	SRT1720 inhibits the reaction [TGFB2 protein results in increased expression of ACTA2 mRNA]	25707573
D020058	Styrene	Styrene affects the expression of TGFB2 mRNA	16705669
D020058	Styrene	Styrene affects the expression of TGFB2 protein	16705669
C013690	styrene oxide	styrene oxide affects the expression of TGFB2 mRNA	16705669
C013690	styrene oxide	styrene oxide affects the expression of TGFB2 protein	16705669
D018170	Sumatriptan	[Naproxen co-treated with Sumatriptan] inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D018170	Sumatriptan	Sumatriptan inhibits the reaction [Capsaicin results in increased expression of TGFB2 protein]	22150557
D000077210	Sunitinib	Sunitinib results in increased expression of TGFB2 mRNA	31533062
C061133	tamibarotene	tamibarotene results in increased secretion of TGFB2 protein	17611697
C061133	tamibarotene	TGFB2 results in increased susceptibility to tamibarotene	17611697
D013629	Tamoxifen	Tamoxifen affects the expression of TGFB2 mRNA	14699072
D013629	Tamoxifen	[Tamoxifen co-treated with ESR2 protein] results in increased expression of TGFB2 mRNA	19059307
C501413	tesaglitazar	tesaglitazar results in increased expression of TGFB2 mRNA	21515302
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of TGFB2 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of TGFB2 mRNA	21592394
C020806	tetrabromobisphenol A	tetrabromobisphenol A results in decreased expression of TGFB2 mRNA	25172293
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of TGFB2 mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased chemical synthesis of TGFB2 mRNA	1447203
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TGFB2 mRNA	1447203; 19619570;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TGFB2 protein	9787404
D013749	Tetrachlorodibenzodioxin	AHR protein promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of TGFB2 mRNA]	15034205
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of TGFB2 mRNA	26377647
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TGFB2 mRNA	19933214; 21097750; 21131560; 24035824;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of TGFB2 protein	17056225
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of TGFB2 mRNA	14728982; 27562557;
D013755	Tetradecanoylphorbol Acetate	[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of TGFB2 mRNA	16979875
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFB2 mRNA	25613284
D013853	Thioacetamide	Cysteine inhibits the reaction [Thioacetamide results in increased expression of TGFB2 mRNA]	15158331
D013853	Thioacetamide	[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of TGFB2 mRNA	23830814
D013853	Thioacetamide	Methionine inhibits the reaction [Thioacetamide results in increased expression of TGFB2 mRNA]	15158331
D013853	Thioacetamide	Thioacetamide results in increased expression of TGFB2 mRNA	15158331; 17292413;
D008063	Thioctic Acid	[Diethylnitrosamine co-treated with Thioacetamide co-treated with Thioctic Acid] affects the expression of TGFB2 mRNA	23830814
D008063	Thioctic Acid	[Thioctic Acid co-treated with Propylthiouracil] results in increased expression of TGFB2 mRNA	31068541
D013893	Thiram	Thiram results in decreased expression of TGFB2 mRNA	20530235
C016151	tinuvin	tinuvin analog results in decreased expression of TGFB2 mRNA	30315675
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of TGFB2 protein	30291989
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in increased expression of TGFB2 mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of TGFB2 mRNA	25729387
C483909	torcetrapib	torcetrapib results in increased expression of TGFB2 mRNA	23228038
D014118	Toxins, Biological	Toxins, Biological affects the expression of TGFB2 mRNA	19682533
D014148	Tranexamic Acid	Tranexamic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TGFB2 mRNA]	24633426
C528105	trans-3,4'-dimethyl-3-hydroxyflavanone	trans-3,4'-dimethyl-3-hydroxyflavanone results in decreased activity of TGFB2 protein	18310908
D014212	Tretinoin	Tretinoin results in increased expression of TGFB2 mRNA	20530235
D014212	Tretinoin	IFNG protein inhibits the reaction [Tretinoin results in increased expression of TGFB2 mRNA]	16007204
D014212	Tretinoin	Tretinoin results in increased expression of TGFB2 mRNA	15955085; 16007204; 17196394;
D014212	Tretinoin	Tretinoin results in increased expression of TGFB2 protein	15955085; 15970678;
D014212	Tretinoin	Tretinoin results in increased secretion of TGFB2 protein	15970678; 16473924;
D014212	Tretinoin	[bisphenol A co-treated with Tretinoin] results in decreased expression of TGFB2 mRNA	30951980
D014212	Tretinoin	[bisphenol F co-treated with Tretinoin] results in decreased expression of TGFB2 mRNA	30951980
D014212	Tretinoin	Tretinoin affects the expression of TGFB2 mRNA	16235736
C032910	triadimefon	triadimefon results in decreased expression of TGFB2 mRNA	26705709
C032910	triadimefon	triadimefon results in decreased expression of TGFB2 mRNA	18976680
D014241	Trichloroethylene	Trichloroethylene results in increased expression of TGFB2 mRNA	15363585
C012589	trichostatin A	trichostatin A results in decreased expression of TGFB2 mRNA	24935251
C012589	trichostatin A	trichostatin A results in increased expression of TGFB2 mRNA	24935251; 26705709;
D014302	Trinitrobenzenesulfonic Acid	Trinitrobenzenesulfonic Acid results in decreased expression of TGFB2 mRNA	25307695
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]	18253093
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased expression of FN1 mRNA]	18253093
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased expression of FN1 protein]	18253093
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD2 protein]	18253093
D000077288	Troglitazone	Troglitazone inhibits the reaction [TGFB2 protein results in increased phosphorylation of and affects the localization of SMAD3 protein]	18253093
D000077288	Troglitazone	Troglitazone results in decreased susceptibility to TGFB2 protein	18253093
D000077288	Troglitazone	Troglitazone results in increased expression of TGFB2 mRNA	17569031
D000077288	Troglitazone	Troglitazone results in increased expression of TGFB2 mRNA	21515302
D014520	Urethane	Freund's Adjuvant inhibits the reaction [Urethane results in decreased expression of TGFB2 mRNA]	12810352
D014520	Urethane	IFNG protein inhibits the reaction [Urethane results in decreased expression of TGFB2 mRNA]	12810352
D014520	Urethane	Urethane results in decreased expression of TGFB2 mRNA	12810352
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TGFB2 mRNA	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of TGFB2 mRNA	24935251; 29154799;
D014635	Valproic Acid	Valproic Acid results in decreased methylation of TGFB2 gene	29154799
D014635	Valproic Acid	Valproic Acid results in increased expression of TGFB2 mRNA	23179753; 26272509;
C066075	vanadium pentoxide	vanadium pentoxide results in decreased expression of TGFB2 mRNA	17459161
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of TGFB2 gene	25560391
C025643	vinclozolin	vinclozolin affects the expression of TGFB2 mRNA	19015723
C029297	vinylidene chloride	vinylidene chloride results in increased expression of TGFB2 mRNA	26682919
D014800	Vitallium	Vitallium analog results in decreased expression of TGFB2 mRNA	23825117
D015025	Zearalenone	Zearalenone results in decreased expression of TGFB2 mRNA	27862621; 29758222;
D015032	Zinc	[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of TGFB2 mRNA	16979875
D015032	Zinc	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
D015032	Zinc	Zinc inhibits the reaction [arsenite inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
D015032	Zinc	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD2 protein]]	26354774
D015032	Zinc	Zinc inhibits the reaction [monomethylarsonous acid inhibits the reaction [TGFB2 protein affects the localization of SMAD3 protein]]	26354774
D015034	Zinc Oxide	Zinc Oxide affects the expression of TGFB2 mRNA	28648595
D000077211	Zoledronic Acid	Zoledronic Acid results in increased expression of TGFB2 mRNA	24714768

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-0993	Aortic aneurysm
KW-0160	Chromosomal rearrangement
KW-0165	Cleavage on pair of basic residues
KW-0903	Direct protein sequencing
KW-0225	Disease mutation
KW-1015	Disulfide bond
KW-0272	Extracellular matrix
KW-0325	Glycoprotein
KW-0339	Growth factor
KW-0497	Mitogen
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0732	Signal

Interpro

InterPro ID	InterPro Term
IPR029034	Cystine-knot_cytokine
IPR001839	TGF-b_C
IPR001111	TGF-b_propeptide
IPR016319	TGF-beta
IPR015615	TGF-beta-rel
IPR003940	TGFb2
IPR017948	TGFb_CS

PROSITE

PROSITE ID	PROSITE Term
PS00250	TGF_BETA_1
PS51362	TGF_BETA_2

Pfam

Pfam ID	Pfam Term
PF00019	TGF_beta
PF00688	TGFb_propeptide

Gene: TGFB2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction